<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAR</journal-id>
<journal-id journal-id-type="hwp">sptar</journal-id>
<journal-id journal-id-type="nlm-ta">Ther Adv Respir Dis</journal-id>
<journal-title>Therapeutic Advances in Respiratory Disease</journal-title>
<issn pub-type="ppub">1753-4658</issn>
<issn pub-type="epub">1753-4666</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1753465812472940</article-id>
<article-id pub-id-type="publisher-id">10.1177_1753465812472940</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reactive oxygen species as therapeutic targets in pulmonary hypertension</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Freund-Michel</surname><given-names>Véronique</given-names></name>
<aff id="aff1-1753465812472940">Laboratoire de Pharmacologie - INSERM U1045, UFR des Sciences Pharmaceutiques, Université Bordeaux Segalen, Case 83, 146 Rue Léo Saignat, 33076 Bordeaux Cedex, France</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Guibert</surname><given-names>Christelle</given-names></name>
<aff id="aff2-1753465812472940">INSERM U1045 ‘Centre de Recherche Cardio-thoracique de Bordeaux’, Bordeaux, France and Université Bordeaux Segalen, Bordeaux, France</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Dubois</surname><given-names>Mathilde</given-names></name>
<aff id="aff3-1753465812472940">INSERM U1045 ‘Centre de Recherche Cardio-thoracique de Bordeaux’, Bordeaux, France and Université Bordeaux Segalen, Bordeaux, France</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Courtois</surname><given-names>Arnaud</given-names></name>
<aff id="aff4-1753465812472940">INSERM U1045 ‘Centre de Recherche Cardio-thoracique de Bordeaux’, Bordeaux, France and Université Bordeaux Segalen, Bordeaux, France</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Marthan</surname><given-names>Roger</given-names></name>
<aff id="aff5-1753465812472940">INSERM U1045 ‘Centre de Recherche Cardio-thoracique de Bordeaux’, Bordeaux, France and Université Bordeaux Segalen, Bordeaux, France</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Savineau</surname><given-names>Jean-Pierre</given-names></name>
<aff id="aff6-1753465812472940">INSERM U1045 ‘Centre de Recherche Cardio-thoracique de Bordeaux’, Bordeaux, France and Université Bordeaux Segalen, Bordeaux, France</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Muller</surname><given-names>Bernard</given-names></name>
<aff id="aff7-1753465812472940">INSERM U1045 ‘Centre de Recherche Cardio-thoracique de Bordeaux’, Bordeaux, France and Université Bordeaux Segalen, Bordeaux, France</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1753465812472940"><email>veronique.michel@u-bordeaux2.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>7</volume>
<issue>3</issue>
<fpage>175</fpage>
<lpage>200</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Pulmonary hypertension (PH) is characterized by a progressive elevation of pulmonary arterial pressure due to alterations of both pulmonary vascular structure and function. This disease is rare but life-threatening, leading to the development of right heart failure. Current PH treatments, designed to target altered pulmonary vascular reactivity, include vasodilating prostanoids, phosphodiesterase-5 inhibitors and endothelin-1 receptor antagonists. Although managing to slow the progression of the disease, these molecules still do not cure PH. More effective treatments need to be developed, and novel therapeutic strategies, targeting in particular vascular remodelling, are currently under investigation. Reactive oxygen species (ROS) are important physiological messengers in vascular cells. In addition to atherosclerosis and other systemic vascular diseases, emerging evidence also support a role of ROS in PH pathogenesis. ROS production is increased in animal models of PH, associated with NADPH oxidases increased expression, in particular of several Nox enzymes thought to be the major source of ROS in the pulmonary vasculature. These increases have also been observed <italic>in vitro</italic> and <italic>in vivo</italic> in humans. Moreover, several studies have shown either the deleterious effect of agents promoting ROS generation on pulmonary vasculature or, conversely, the beneficial effect of antioxidant agents in animal models of PH. In these studies, ROS production has been directly linked to pulmonary vascular remodelling, endothelial dysfunction, altered vasoconstrictive responses, inflammation and modifications of the extracellular matrix, all important features of PH pathophysiology. Altogether, these findings indicate that ROS are interesting therapeutic targets in PH. Blockade of ROS-dependent signalling pathways, or disruption of sources of ROS in the pulmonary vasculature, targeting in particular Nox enzymes, represent promising new therapeutic strategies in this disease.</p>
</abstract>
<kwd-group>
<kwd>endothelial dysfunction</kwd>
<kwd>inflammation</kwd>
<kwd>NAPDH oxidases</kwd>
<kwd>Nox enzymes</kwd>
<kwd>pulmonary hypertension (PH)</kwd>
<kwd>pulmonary vasculature</kwd>
<kwd>reactive oxygen species (ROS)</kwd>
<kwd>vascular hyperreactivity</kwd>
<kwd>vascular remodelling</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1753465812472940" sec-type="intro">
<title>Introduction</title>
<p>Pulmonary hypertension (PH) is a rare and severe disease, with a progressive elevation of pulmonary arterial pressure (PAP) often leading to right heart failure. Therapeutic strategies currently available, mostly designed to induce vasodilation, alleviate PH symptoms but do not afford a cure. Clinical worsening leads to a necessary heart/lung graft with reduced life expectancy. PH cellular and molecular mechanisms are therefore under investigation in order to define new therapeutic targets. Among the new potential strategies that have emerged recently, targeting of reactive oxygen species (ROS) appears as an interesting approach in PH treatment. Indeed, ROS play important physiological roles in the pulmonary vasculature, and recent studies have also evidenced a role for ROS in PH pathophysiology.</p>
<p>After a brief summary of PH pathophysiology and treatments currently available, this review will provide information about ROS production and metabolism in the pulmonary vasculature, ROS-dependent signalling pathways in pulmonary vascular cells and will summarize the data showing a role for ROS in the pathogenesis of PH.</p>
</sec>
<sec id="section2-1753465812472940">
<title>Pathophysiology of PH</title>
<p>PH is defined as an elevation of mean PAP above 25 mmHg at rest, compared with normal mean PAP comprised between 10 and 15 mmHg [<xref ref-type="bibr" rid="bibr180-1753465812472940">Simonneau <italic>et al.</italic> 2009</xref>]. PH is characterized by both functional and structural modifications of pulmonary arteries, leading to altered pulmonary vascular reactivity and remodelling of the pulmonary arterial wall [<xref ref-type="bibr" rid="bibr176-1753465812472940">Schermuly <italic>et al.</italic> 2011</xref>]. These mechanisms are associated with thrombotic lesions of pulmonary arteries [<xref ref-type="bibr" rid="bibr88-1753465812472940">Humbert <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr207-1753465812472940">Voelkel <italic>et al.</italic> 2012</xref>]. Increased pulmonary vascular resistance leads to increase in right heart work to maintain cardiac output, ultimately leading to right heart failure and death. PH classification has been updated recently and PH forms are now divided into five categories: pulmonary arterial hypertension belongs to group 1, being idiopathic, familial or associated with other diseases including for example connective tissue diseases, HIV infection, congenital heart disease or portal hypertension. Group 2 includes PH caused by left-sided heart disease, such as for example cardiomyopathy, diastolic dysfunction or aorticstenosis. Secondary PH forms associated with chronic respiratory diseases such as chronic obstructive pulmonary diseases or pulmonary fibrosis are often named ‘hypoxic’ PH and belong to group 3. Group 4 includes PH due to pulmonary embolus or pulmonary thrombosis. Group 5 includes PH due to other miscellaneous causes, which do not fit into the other four categories [<xref ref-type="bibr" rid="bibr180-1753465812472940">Simonneau <italic>et al.</italic> 2009</xref>].</p>
<p>Altered pulmonary vascular reactivity evidenced in PH is characterized by an increased contraction associated with a decreased endothelium-dependent relaxation of pulmonary arteries. This phenomenon is due in particular to an endothelial dysfunction leading to an imbalance in the production/bioactivity of both vasoconstrictive mediators such as serotonin or endothelin-1 and vasodilators such as nitric oxide (NO) or prostacyclin (PGI<sub>2</sub>) [<xref ref-type="bibr" rid="bibr88-1753465812472940">Humbert <italic>et al.</italic> 2004</xref>]. The function of the pulmonary arterial smooth muscle is also modified, with altered contractile signalling pathways, such as the RhoA/ROCK pathway [<xref ref-type="bibr" rid="bibr34-1753465812472940">Connolly and Aaronson, 2011</xref>], and decreased expression/activity of ions channels, such as voltage-gated potassium channels [<xref ref-type="bibr" rid="bibr75-1753465812472940">Guibert <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr172-1753465812472940">Rhodes <italic>et al.</italic> 2009</xref>], leading to excessive contraction of pulmonary arteries.</p>
<p>Structural changes observed in pulmonary arteries, also called pulmonary vascular remodelling, include medial and adventitial thickening in proximal arteries, due to decreased apoptosis, hyperplasia and hypertrophy of smooth muscle cells and of fibroblasts associated with excessive accumulation of matrix proteins [<xref ref-type="bibr" rid="bibr136-1753465812472940">Morrell <italic>et al.</italic> 2009</xref>]. Formation of a neointima is also observed, due to accumulation of smooth muscle cells and myofibroblasts, together with the formation of plexiform lesions resulting from excessive and disorganized smooth muscle and endothelial cell proliferation. In normally nonmuscular distal arteries, formation of a media <italic>de novo</italic> is observed, resulting from recruitment, differentiation and proliferation of fibroblasts and progenitor cells [<xref ref-type="bibr" rid="bibr82-1753465812472940">Hassoun <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr176-1753465812472940">Schermuly <italic>et al.</italic> 2011</xref>]. All of these structural changes are therefore leading to arterial wall thickening, thus contributing to the increased pulmonary vascular resistance and elevation of PAP observed in PH.</p>
</sec>
<sec id="section3-1753465812472940">
<title>Current treatments of PH</title>
<p>The current therapeutic strategy developed for PH is to associate a ‘specific’ treatment, against excessive pulmonary vascular contraction and remodelling, to a more ‘conventional’ treatment dedicated to alleviate symptoms, effort and right heart failure [<xref ref-type="bibr" rid="bibr60-1753465812472940">Frumkin, 2012</xref>; <xref ref-type="bibr" rid="bibr146-1753465812472940">O’Callaghan <italic>et al.</italic> 2011</xref>]. Conventional treatments comprise lifestyle modification, diuretics to alleviate right heart failure, anticoagulant therapies to reduce risks of thrombotic lesions and oxygen therapy to treat hypoxemia [<xref ref-type="bibr" rid="bibr64-1753465812472940">Galie <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr180-1753465812472940">Simonneau <italic>et al.</italic> 2009</xref>]. Whereas nonselective systemic vasodilators such as calcium channel blockers are effective only in a few groups of responding patients [<xref ref-type="bibr" rid="bibr134-1753465812472940">Montani <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr174-1753465812472940">Rubin, 1985</xref>; <xref ref-type="bibr" rid="bibr194-1753465812472940">Tonelli <italic>et al.</italic> 2010</xref>], more specific vasodilator treatments have been developed for the treatment of PH. Three families of molecules are currently used: vasodilating prostanoids, phosphodiesterase-5 inhibitors and endothelin-1 receptor antagonists [<xref ref-type="bibr" rid="bibr60-1753465812472940">Frumkin, 2012</xref>].</p>
<p>Prostacyclin, also named prostaglandin I<sub>2</sub> (PGI<sub>2</sub>), is a potent vasodilator whose endothelial production is decreased in PH. This decrease therefore contributes to excessive pulmonary arterial contraction, but also to pulmonary vascular remodelling, since PGI<sub>2</sub> normally also inhibits smooth muscle proliferation, platelet aggregation and exerts anti-inflammatory actions [<xref ref-type="bibr" rid="bibr67-1753465812472940">Gomberg-Maitlandand Olschewski, 2008</xref>]. Prostacyclin therapy has therefore been employed for over 25 years to treat PH and showed efficiency in alleviating symptoms, and even in increasing patient survival for epoprostenol [<xref ref-type="bibr" rid="bibr181-1753465812472940">Sitbon <italic>et al.</italic> 2002</xref>]. However, because of its complex intravenous administration and its numerous adverse effects, more stable prostacyclin analogues have been developed with other routes of administration, in particular orally, subcutaneously or inhaled active compounds [<xref ref-type="bibr" rid="bibr221-1753465812472940">Yildiz, 2009</xref>]. Therapy strategies combining oral prostacyclin analogues with phosphodiesterase-5 inhibitors and/or endothelin-1 receptor antagonists have also been developed to enhance therapeutic efficiency.</p>
<p>Endothelin-1, activating ET<sub>A</sub> and ET<sub>B</sub> receptors, is a potent vasoconstrictor and also participates in smooth muscle proliferation, fibrosis and inflammation [<xref ref-type="bibr" rid="bibr102-1753465812472940">Kim and Rubin, 2002</xref>]. Activation of ET<sub>A</sub> receptors, mainly expressed on smooth muscle cells, induces vasoconstriction whereas activation of ET<sub>B</sub> receptors, also expressed on endothelial cells, induces NO release and vasodilation [<xref ref-type="bibr" rid="bibr49-1753465812472940">Dupuis, 2001</xref>]. However, both ET<sub>A</sub> selective antagonists such as ambrisentan and dual ET<sub>A</sub>/ET<sub>B</sub> antagonists such as bosentan are used in clinics and have all been shown to alleviate PH symptoms and to improve exercise capacity [<xref ref-type="bibr" rid="bibr62-1753465812472940">Galie <italic>et al.</italic> 2008a</xref>, <xref ref-type="bibr" rid="bibr63-1753465812472940">2008b</xref>; <xref ref-type="bibr" rid="bibr146-1753465812472940">O’Callaghan <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr175-1753465812472940">Rubin <italic>et al.</italic> 2002</xref>].</p>
<p>NO-mediated relaxation of the pulmonary vascular smooth muscle involves synthesis of cyclic guanosine monophosphate (cGMP), which is then degraded by phosphodiesterase-5 (PDE5). Inhibitors of PDE5 such as sildenafil and tadalafil are therefore also used in PH treatment. PDE5 is abundantly expressed in the pulmonary vasculature [<xref ref-type="bibr" rid="bibr79-1753465812472940">Hanson <italic>et al.</italic> 1998</xref>; <xref ref-type="bibr" rid="bibr154-1753465812472940">Pauvert <italic>et al.</italic> 2003</xref>] and PDE5 inhibitors induce beneficial pulmonary vasodilation and antiproliferative effects in PH patients [<xref ref-type="bibr" rid="bibr4-1753465812472940">Archer and Michelakis, 2009</xref>; <xref ref-type="bibr" rid="bibr133-1753465812472940">Montani <italic>et al.</italic> 2009</xref>].</p>
<p>In summary, the great progress made in the comprehension of PH pathophysiological mechanisms has led to the development of these specific treatments and greatly improved patient’s clinical course and life expectancy. However, although being able to alleviate PH symptoms, these treatments still do not afford a cure, and this shows the need to persevere in the comprehension of PH cellular and molecular mechanisms in order to define new therapeutic strategies. Among the various targets under investigation at the moment, targeting of ROS appears as an interesting new approach in PH treatment.</p>
</sec>
<sec id="section4-1753465812472940">
<title>Targeting ROS as a novel therapeutic strategy in PH</title>
<p>ROS are cellular products derived from oxygen metabolism. Depending on their local concentration, ROS can play physiological but also pathophysiological roles, becoming harmful to cells. Indeed, at low concentrations, ROS are intracellular signalling messengers, and ROS production is counterbalanced by antioxidant systems contributing to ROS metabolism [<xref ref-type="bibr" rid="bibr198-1753465812472940">Touyz, 2004</xref>]. However, an imbalance between ROS production and ROS metabolism can lead to increased ROS levels, a situation named oxidative stress, with alteration by oxidation of essential cellular components such as lipids, proteins, mitochondria and even DNA, which can ultimately lead to cell death.</p>
<p>The vasculature is an important source of ROS [<xref ref-type="bibr" rid="bibr198-1753465812472940">Touyz, 2004</xref>], and many studies have shown a role for ROS in vascular physiology and pathophysiology. Indeed, oxidative stress is a mediator of vascular injury in cardiovascular diseases such as systemic hypertension [<xref ref-type="bibr" rid="bibr198-1753465812472940">Touyz, 2004</xref>], atherosclerosis [<xref ref-type="bibr" rid="bibr205-1753465812472940">Victor <italic>et al.</italic> 2009</xref>] or ischemia–reperfusion [<xref ref-type="bibr" rid="bibr138-1753465812472940">Murphy and Steenbergen, 2008</xref>]. A growing body of evidence, summarized in the following sections, also demonstrates a role for ROS and for oxidative stress in various aspects of PH pathophysiology.</p>
<sec id="section5-1753465812472940">
<title>Production and metabolism of ROS in the pulmonary vasculature</title>
<sec id="section6-1753465812472940">
<title>Biology of ROS</title>
<p>Many products are generated in normal cell respiration, derived from the reduction of molecular oxygen and all termed ROS. However, ROS have different chemical properties, being either free or nonfree radicals. Indeed, some ROS have an unpaired electron on their outer orbital, such as superoxide (<inline-formula id="inline-formula1-1753465812472940"><mml:math display="inline" id="math1-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>) or the hydroxyl radical (HO<sup>●</sup>), leading to a high chemical reactivity. Other ROS, such as hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), peroxynitrites (ONOO<sup>-</sup>), hypochlorous acid (HOCl), ozone (O<sub>3</sub>), singlet oxygen (<sup>1</sup>O<sub>2</sub>) or lipid peroxides (LOOH), although lacking an unpaired electron, are still chemically reactive by exchanging some electrons with other molecules [<xref ref-type="bibr" rid="bibr76-1753465812472940">Guzik and Harrison, 2006</xref>].</p>
<p>ROS generation often begins with one- or two-electron reduction of molecular oxygen to form <inline-formula id="inline-formula2-1753465812472940"><mml:math display="inline" id="math2-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> or H<sub>2</sub>O<sub>2</sub> (<xref ref-type="fig" rid="fig1-1753465812472940">Figure 1</xref>). Under ambient conditions, superoxide then rapidly dismutates to H<sub>2</sub>O<sub>2</sub>, either spontaneously, or catalysed by superoxide dismutase (SOD). H<sub>2</sub>O<sub>2</sub> is then converted into water by catalase, extracellular glutathione peroxidase or thiols. When H<sub>2</sub>O<sub>2</sub> is bound to peroxidases such as catalase, it also forms a metabolite named compound I which can oxidize NO<sup>●</sup> to nitrogen dioxide anion NO<sub>2</sub><sup>-</sup> . Compound I can then react with NO<sub>2</sub><sup>-</sup> to form nitrogen dioxide radical <inline-formula id="inline-formula3-1753465812472940"><mml:math display="inline" id="math3-1753465812472940"><mml:mrow><mml:msub><mml:mtext>NO</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> which can induce nitrosylation reactions on protein tyrosine residues or on lipids [<xref ref-type="bibr" rid="bibr173-1753465812472940">Rubbo <italic>et al.</italic> 2009</xref>]. Finally, H<sub>2</sub>O<sub>2</sub> can also undergo a Fenton reaction in the presence of heavy metals to form the highly reactive hydroxyl radical HO<sup>●</sup>. H<sub>2</sub>O<sub>2</sub> and HO<sup>●</sup> can then oxidize lipids, proteins and DNA, and can lead to pathological cell response when being produced in excess [<xref ref-type="bibr" rid="bibr25-1753465812472940">Cai, 2005</xref>].</p>
<fig id="fig1-1753465812472940" position="float">
<label>Figure 1.</label>
<caption>
<p>Generation and metabolism of ROS.</p>
<p>Molecular oxygen can undergo electronic rearrangement to form singlet oxygen (<sup>1</sup>O<sub>2</sub>). Molecular oxygen can also form superoxide (<inline-formula id="inline-formula4-1753465812472940"><mml:math display="inline" id="math4-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>) or hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) after one or two electron reduction, respectively. <inline-formula id="inline-formula5-1753465812472940"><mml:math display="inline" id="math5-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> can rapidly react with nitric oxide (NO<sup>●</sup>) to form peroxynitrites (ONOO-). H<sub>2</sub>O<sub>2</sub> is also produced after <inline-formula id="inline-formula6-1753465812472940"><mml:math display="inline" id="math6-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> dismutation, either spontaneously, or through action of superoxide dismutase (SOD). H<sub>2</sub>O<sub>2</sub> can then produce the hydroxyl radical (HO<sup>●</sup>), after one electron reduction, through the Fenton reaction, or indirectly through generation of hypochlorous acid (HOCl). HO<sup>●</sup> is then degraded to water. H<sub>2</sub>O<sub>2</sub> can also be directly converted to water by catalase. In addition, H<sub>2</sub>O<sub>2</sub> can also oxidize Fe<sup>3+</sup>-containing enzymes to produce compound I which can oxidize NO<sup>●</sup> to form nitrogen dioxide anion (NO<sub>2</sub>-), therefore leading to formation of nitrogen dioxide radical (N<inline-formula id="inline-formula7-1753465812472940"><mml:math display="inline" id="math7-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>). All of these highly reactive species (shown in blue) can then alter lipids, proteins and DNA function through oxidation, nitrosation and nitration reactions.</p>
</caption>
<graphic xlink:href="10.1177_1753465812472940-fig1.tif"/>
</fig>
</sec>
<sec id="section7-1753465812472940">
<title>Sources of ROS in the pulmonary vasculature</title>
<p>In mammalian cells, enzymatic sources of ROS include NADPH oxidases, uncoupled nitric oxide synthase (NOS), cytochromes P450, xanthine oxidase (XO), the mitochondrial electron transport chain, and other enzymes such as lipoxygenases, cyclooxygenases or peroxidases as well as hemoproteins such as heme and hematin [<xref ref-type="bibr" rid="bibr71-1753465812472940">Griendling <italic>et al.</italic> 2000</xref>]. All vascular cell types are able to produce ROS either from metabolic or from enzymatic sources. However, in the pulmonary vasculature, ROS main sources are NADPH oxidases, uncoupled endothelial NOS (eNOS), XO as well as the mitochondrial electron transport chain [<xref ref-type="bibr" rid="bibr117-1753465812472940">Li and Shah, 2004</xref>; <xref ref-type="bibr" rid="bibr122-1753465812472940">Lyle and Griendling, 2006</xref>].</p>
<sec id="section8-1753465812472940">
<title>NAPDH oxidases</title>
<p>NADPH oxidases are enzymes composed of multiple subunits that catalyse <inline-formula id="inline-formula8-1753465812472940"><mml:math display="inline" id="math8-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> production after O<sub>2</sub> reduction, using NADPH (reduced form of the nicotinamide adenine dinucleotide phosphate NADP) as the electron donor [<xref ref-type="bibr" rid="bibr177-1753465812472940">Sedeek <italic>et al.</italic> 2009</xref>]. NADPH oxidases were initially identified in phagocytes of the innate immune response, where they produce large amounts of <inline-formula id="inline-formula9-1753465812472940"><mml:math display="inline" id="math9-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and contribute to the extracellular oxidative burst dedicated to kill invading pathogens [<xref ref-type="bibr" rid="bibr161-1753465812472940">Quinn and Gauss, 2004</xref>]. These NADPH oxidases were therefore termed phox (standing for phagocyte oxidase). However, NADPH oxidases were later also identified in nonphagocytic cells, and the term Nox (standing for NAPDH oxidase) was introduced to designate these nonphagocytic NADPH oxidases [<xref ref-type="bibr" rid="bibr21-1753465812472940">Brandes <italic>et al.</italic> 2010</xref>].</p>
<p>The mammalian Nox family comprises seven members: Nox1, Nox2, Nox3, Nox4, Nox5, Duox1 and Duox2 [<xref ref-type="bibr" rid="bibr21-1753465812472940">Brandes <italic>et al.</italic> 2010</xref>]. They all differ in their mode of activation, expression, and/or interaction with other proteins. In the cardiovascular system, Nox1, Nox2, Nox4 and Nox5 have been detected [<xref ref-type="bibr" rid="bibr21-1753465812472940">Brandes <italic>et al.</italic> 2010</xref>]. The prototypical phagocytic NADPH oxidase (Nox2) is composed of five subunits (<xref ref-type="fig" rid="fig2-1753465812472940">Figure 2</xref>): the two membrane-bound subunits gp91phox (the catalytic subunit, also termed Nox2) and p22phox, forming a heterodimeric complex named cytochrome b558, and the three cytosolic subunits p40phox, p47phox and p67phox. In stimulated cells, p47phox phosphorylation leads to assembly of the three cytosolic subunits to form a complex that translocates to the membrane and associates with cytochrome b558 to assemble the active oxidase [<xref ref-type="bibr" rid="bibr199-1753465812472940">Touyz and Briones, 2010</xref>]. This activation also requires the small G proteins Rac (Rac1 or Rac2) and Rap1A [<xref ref-type="bibr" rid="bibr15-1753465812472940">Bokoch and Knaus, 2003</xref>]. Nox1 is the closest homolog of Nox2, and requires the membrane subunit p22phox as well as at least two other cytosolic subunits termed Noxo1 (Nox organizer 1, which is a p47phox analogue) and Noxa1 (Nox activator 1, which is a p67phox analogue) (<xref ref-type="fig" rid="fig2-1753465812472940">Figure 2</xref>). Nox4 was initially termed Renox (for renal oxidase, as its expression is abundant in the kidney). Nox4 differs from Nox1 and Nox2 in the fact that it mainly produces H<sub>2</sub>O<sub>2</sub> directly, whereas Nox1 and Nox2 first produce <inline-formula id="inline-formula10-1753465812472940"><mml:math display="inline" id="math10-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> that is then converted to H<sub>2</sub>O<sub>2</sub>. Moreover, although Nox4 also requires the membrane subunit p22phox for its activity, it does not seem to require recruitment of the cytosolic subunits p40phox, p47phox, p67phox or of any small G protein (<xref ref-type="fig" rid="fig2-1753465812472940">Figure 2</xref>). Nox4 is therefore the only NADPH oxidase being able to produce ROS constitutively. In contrast to the other Nox isoforms, Nox5 is expressed in humans but not in rodents. Moreover, Nox5 does not require the membrane subunit p22phox or any other cytosolic subunit for its activity. It is the only Nox isoform that is directly activated by Ca<sup>2+</sup>, due to the presence of four Ca<sup>2+</sup> binding sites (EF hands) in its amino terminus [<xref ref-type="bibr" rid="bibr93-1753465812472940">Jagnandan <italic>et al.</italic> 2007</xref>].</p>
<fig id="fig2-1753465812472940" position="float">
<label>Figure 2.</label>
<caption>
<p>Structure of NADPH oxidases expressed in pulmonary arteries.</p>
<p>Nox core structure consists of six transmembrane domains (shown in blue) and a cytosolic C-terminal end. Nox1, 2 and 4 are constitutively associated to the membrane-bound subunit p22phox (shown in yellow), that acts as a maturation and stabilization partner. Regulatory cytosolic subunits are necessary for Nox1 and Nox2 structure and activity. Nox1 associates with Noxo1 and Noxa1. Nox2 associates with p40phox, p47phox and p67phox. Both Nox1 and Nox2 associate with the small G protein Rac1 and/or Rac2. Noxa1, p40phox and p47phox are cytosolic organizers (shown in orange), whereas Noxa1 and p67phox (shown in green) as well as Rac proteins (shown in purple) participate to Nox1 and Nox2 activity. By contrast, Nox4 does not require any cytosolic subunit for its structure or activity.</p>
</caption>
<graphic xlink:href="10.1177_1753465812472940-fig2.tif"/>
</fig>
<p>In the lung, expression of the membrane-bound subunits Nox1, Nox2, Nox4 and p22phox have been shown in pulmonary vessels, together with expression of the cytosolic subunits Noxa1, Noxo1, p40phox, p47phox and p67phox [<xref ref-type="bibr" rid="bibr156-1753465812472940">Perez-Vizcaino <italic>et al.</italic> 2010</xref>] (<xref ref-type="fig" rid="fig2-1753465812472940">Figures 2</xref> and <xref ref-type="fig" rid="fig3-1753465812472940">3</xref>). In cultured cells, expression of Nox2 and Nox4 has been reported in pulmonary arterial endothelial cells (PAECs) [<xref ref-type="bibr" rid="bibr9-1753465812472940">Bayraktutan <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr72-1753465812472940">Griffith <italic>et al.</italic> 2009</xref>], in adventitial fibroblasts [<xref ref-type="bibr" rid="bibr83-1753465812472940">Haurani and Pagano, 2007</xref>], and in pulmonary arterial smooth muscle cells (PASMCs) [<xref ref-type="bibr" rid="bibr20-1753465812472940">Brandes and Kreuzer, 2005</xref>; <xref ref-type="bibr" rid="bibr132-1753465812472940">Mittal <italic>et al.</italic> 2007</xref>]. In all of these cells, Nox4 is the predominant Nox isoform expressed [<xref ref-type="bibr" rid="bibr156-1753465812472940">Perez-Vizcaino <italic>et al.</italic> 2010</xref>]. Nox1 expression seems to be restricted to PASMCs and is present in low concentrations in basal states of these cells [<xref ref-type="bibr" rid="bibr132-1753465812472940">Mittal <italic>et al.</italic> 2007</xref>] (<xref ref-type="fig" rid="fig3-1753465812472940">Figure 3</xref>).</p>
<fig id="fig3-1753465812472940" position="float">
<label>Figure 3.</label>
<caption>
<p>Molecular sources of ROS in pulmonary arteries.</p>
<p>In the pulmonary vasculature, all vascular cell types are able to produce ROS. (A) In pulmonary adventitial fibroblasts, the NADPH oxidases Nox2 and Nox4 are expressed and are sources of both superoxide (<inline-formula id="inline-formula11-1753465812472940"><mml:math display="inline" id="math11-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). (B) <inline-formula id="inline-formula12-1753465812472940"><mml:math display="inline" id="math12-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and H<sub>2</sub>O<sub>2</sub> are also produced in pulmonary arterial smooth muscle cells by Nox1, Nox2 and Nox4. In addition, the mitochondrial respiratory chain is also a source of ROS in these cells, where electron transport chain through complexes I to IV can lead to <inline-formula id="inline-formula13-1753465812472940"><mml:math display="inline" id="math13-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> generation by complexes I and III. (C) Nox2, Nox4 and the mitochondrial respiratory chain are also sources of <inline-formula id="inline-formula14-1753465812472940"><mml:math display="inline" id="math14-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and H<sub>2</sub>O<sub>2</sub> in pulmonary endothelial cells. In addition, endothelial nitric oxide synthase (eNOS) can also be a source of <inline-formula id="inline-formula15-1753465812472940"><mml:math display="inline" id="math15-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> when uncoupled, with electrons diverted from L-arginine to molecular oxygen. Finally, xanthine oxidase is also expressed in these cells, and is a source of both <inline-formula id="inline-formula16-1753465812472940"><mml:math display="inline" id="math16-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and H<sub>2</sub>O<sub>2</sub>, through substrate oxidation by a molybdopterin (Mb-pt) moiety and generation of ROS for xanthine oxidase reoxidation. Nox: NADPH oxidase; NADPH: nicotinamide adenine dinucleotide phosphate; CoQ: Coenzyme Q; CytC: cytochrome C; FAD: flavin adenine dinucleotide; FMN: flavin mononucleotide.</p>
</caption>
<graphic xlink:href="10.1177_1753465812472940-fig3.tif"/>
</fig>
</sec>
<sec id="section9-1753465812472940">
<title>Uncoupled endothelial NOS</title>
<p>NOS is the enzyme responsible for NO synthesis. Three isoforms have been identified: NOS1 (neuronal NOS or nNOS), NOS2 (inducible NOS or iNOS) and NOS3 (endothelial NOS or eNOS) [<xref ref-type="bibr" rid="bibr224-1753465812472940">Zuckerbraun <italic>et al.</italic> 2011</xref>]. Active eNOS is a homodimer and catalyses the formation of NO from L-arginine. Each monomer contains a carboxy-terminal reductase domain and an amino-terminal oxygenase domain. The reductase domain is composed of two flavinic cofactors (flavin mononucleotide [FMN] and flavin adenine dinucleotide [FAD]) binding sites and also contains a NADPH binding site. The oxygenase domain contains binding sites for heme, for the substrate L-arginine and for the cofactor tetrahydrobiopterin (BH<sub>4</sub>). Oxygenase and reductase domains are linked with a small sequence of amino acids that contains a calmodulin binding site [<xref ref-type="bibr" rid="bibr2-1753465812472940">Alderton <italic>et al.</italic> 2001</xref>]. Heme groups are essential for dimerization of both monomers and for promoting electron transfer from the flavin to the heme of the other monomer. Finally, a zinc ion binds at both monomers to stabilize the dimeric structure [<xref ref-type="bibr" rid="bibr213-1753465812472940">Weseler and Bast, 2010</xref>]. An electron transfer is catalysed within the reductase domain via the flavins FMN and FAD to the heme in the oxygenase domain. Binding of the calcium-calmodulin complex to the reductase domain facilitates this electron transfer. O<sub>2</sub> is then reduced at the heme of the oxygenase domain and L-arginine is oxidized to L-citrulline and NO<sup>●</sup>. Many signals can regulate eNOS activity, in particular intracellular calcium concentration or phosphorylation in the reductase and calmodulin-binding domains through the action of kinases such as protein-kinase B (PKB, also named Akt), protein-kinase A (PKA) or calmodulin-dependent kinase II (CamKII) [<xref ref-type="bibr" rid="bibr54-1753465812472940">Fleming, 2010</xref>; <xref ref-type="bibr" rid="bibr55-1753465812472940">Forstermann, 2006</xref>].</p>
<p>Under some conditions, eNOS generates <inline-formula id="inline-formula17-1753465812472940"><mml:math display="inline" id="math17-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> rather than NO<sup>●</sup>, a phenomenon that is known as NOS uncoupling: electrons flowing from the reductase domain to the oxygenase domain are diverted to molecular oxygen rather than to L-arginine, with production of <inline-formula id="inline-formula18-1753465812472940"><mml:math display="inline" id="math18-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> from the oxygenase by dissociation of the ferrous–dioxygen complex [<xref ref-type="bibr" rid="bibr10-1753465812472940">Belik <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr106-1753465812472940">Konduri <italic>et al.</italic> 2007</xref>] (<xref ref-type="fig" rid="fig3-1753465812472940">Figure 3</xref>). The limited availability of the cofactor BH<sub>4</sub> seems to play a major role in eNOS uncoupling. Indeed during normal catalytic function of eNOS, BH<sub>4</sub> acts as an electron donor and BH<sub>4</sub> bioavailability depends on a balance between <italic>de novo</italic> synthesis by GTP cyclohydrolase-1 (GTPCH-1, the first and limiting step for BH<sub>4</sub> biosynthesis from GTP), loss of BH<sub>4</sub> (due to oxidation of BH<sub>4</sub> to form dihydrobiopterin BH<sub>2</sub>) and recycling of BH<sub>2</sub> into BH<sub>4</sub> by dihydrofolate reductase (DHFR) [<xref ref-type="bibr" rid="bibr37-1753465812472940">Crabtree and Channon, 2011</xref>]. However, when ROS levels are increased (following activation of NADPH oxidases, for example), <inline-formula id="inline-formula19-1753465812472940"><mml:math display="inline" id="math19-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> can react with NO<sup>●</sup> to the highly reactive ONOO- that is able to oxidize BH4 to BH<sub>2</sub>. When BH<sub>2</sub> is not fully recycled, it can compete with BH<sub>4</sub> for binding to eNOS, resulting in eNOS uncoupling [<xref ref-type="bibr" rid="bibr37-1753465812472940">Crabtree and Channon, 2011</xref>; <xref ref-type="bibr" rid="bibr66-1753465812472940">Gielis <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr144-1753465812472940">Noguchi <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr213-1753465812472940">Weseler and Bast, 2010</xref>]. Rather than absolute BH<sub>4</sub> concentrations, the eNOS/BH<sub>4</sub> stoichiometry and the biopterin redox status now appear as key determinants of eNOS uncoupling [<xref ref-type="bibr" rid="bibr11-1753465812472940">Bendall <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr37-1753465812472940">Crabtree and Channon, 2011</xref>]. Other potential and biopterin-independent mechanisms of eNOS uncoupling include oxidation of the zinc-thiolate cluster of eNOS with subsequent release of zinc [<xref ref-type="bibr" rid="bibr223-1753465812472940">Zou <italic>et al.</italic> 2002</xref>], L-arginine depletion [<xref ref-type="bibr" rid="bibr55-1753465812472940">Forstermann, 2006</xref>], accumulation of the endogenous eNOS inhibitors methylarginines [<xref ref-type="bibr" rid="bibr48-1753465812472940">Druhan <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr55-1753465812472940">Forstermann, 2006</xref>], defect in heat shock protein 90/eNOS interaction [<xref ref-type="bibr" rid="bibr187-1753465812472940">Sud <italic>et al.</italic> 2007</xref>], <italic>S</italic>-glutathionylation of eNOS [<xref ref-type="bibr" rid="bibr86-1753465812472940">Hu <italic>et al.</italic> 2010</xref>] or thiyl radical formation on the enzyme [<xref ref-type="bibr" rid="bibr30-1753465812472940">Chen <italic>et al.</italic> 2011</xref>].</p>
</sec>
<sec id="section10-1753465812472940">
<title>Xanthine oxidase</title>
<p>XO and xanthine dehydrogenase (XDH) are xanthine oxidoreductases (XORs), and are involved in the last steps of purine metabolism, catalysing the transformation of hypoxanthine and xanthine to uric acid [<xref ref-type="bibr" rid="bibr95-1753465812472940">Jarasch <italic>et al.</italic> 1981</xref>]. XO and XDH are encoded by the same gene, and can be interconverted <italic>in vivo</italic> [<xref ref-type="bibr" rid="bibr143-1753465812472940">Nishino <italic>et al.</italic> 2008</xref>]. XDH uses NAD<sup>+</sup> as an electron acceptor, thus producing NADH, whereas XO prefers O<sub>2</sub> as an electron acceptor, therefore generating <inline-formula id="inline-formula20-1753465812472940"><mml:math display="inline" id="math20-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and H<sub>2</sub>O<sub>2</sub>. The ratio of XO to xanthine dehydrogenase in pulmonary vascular cells is therefore critical to determine the amount of ROS produced by this enzyme system in the pulmonary vasculature [<xref ref-type="bibr" rid="bibr18-1753465812472940">Borges <italic>et al.</italic> 2002</xref>].</p>
<p>XO is composed of two monomers, each containing a molybdopterin moiety that catalyses oxidation of a substrate. The accepted electrons are then rapidly transported via a Fe<sub>2</sub>–S<sub>2</sub> centre to the cofactor FAD, which then reduces the oxidant substrate O<sub>2</sub> [<xref ref-type="bibr" rid="bibr80-1753465812472940">Harrison, 2002</xref>]. Reoxidation of XO needs the transfer of six electrons to O<sub>2</sub>, therefore generating two molecules of H<sub>2</sub>O<sub>2</sub> and two molecules of <inline-formula id="inline-formula21-1753465812472940"><mml:math display="inline" id="math21-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> [<xref ref-type="bibr" rid="bibr213-1753465812472940">Weseler and Bast, 2010</xref>] (<xref ref-type="fig" rid="fig3-1753465812472940">Figure 3</xref>). XO expression has been evidenced in the pulmonary arterial endothelium <italic>in vitro</italic> and <italic>in vivo</italic> [<xref ref-type="bibr" rid="bibr151-1753465812472940">Partridge <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr156-1753465812472940">Perez-Vizcaino <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section11-1753465812472940">
<title>Mitochondrial electron transport chain</title>
<p>Mitochondria are also a major source of ROS in the pulmonary vasculature. The mitochondrial matrix contains enzymes that participate in the metabolism of pyruvate and fatty acids to produce acetyl CoA. The matrix also contains enzymes of the citric acid cycle which can then oxidize acetyl CoA to CO<sub>2</sub>, generating three molecules of NADH and one molecule of FADH<sub>2</sub> during this process. NADH and FADH<sub>2</sub> are then used as electron donors by the mitochondrial electron transport chain to generate the proton gradient necessary to produce ATP.</p>
<p>The mitochondrial respiratory chain is the main energy source for the cell. Indeed, more than 95% of O<sub>2</sub> consumed by cells is reduced by four electrons to yield two molecules of H<sub>2</sub>O. This occurs at the inner mitochondrial membrane, via mitochondrial electron transport chain complexes I to IV [<xref ref-type="bibr" rid="bibr13-1753465812472940">Birukov, 2009</xref>; <xref ref-type="bibr" rid="bibr61-1753465812472940">Fuchs <italic>et al.</italic> 2010</xref>] (<xref ref-type="fig" rid="fig3-1753465812472940">Figure 3</xref>). NADH is oxidized by complex I, and FADH<sub>2</sub> is oxidized by complex II, leading to reduction of ubiquinone to ubiquinol. Two electrons are carried by ubiquinol from complex I to complex III (coenzyme Q: cytochromes c-oxidoreductase). Another pair of electrons is transferred to ubiquinone at complex II, and is then also carried by ubiquinol to complex III. In complex III, one electron is transferred at the Q<sub>0</sub> site to the Rieske iron–sulfur protein and then to cytochrome c, while the other electron is transferred to cytochrome b, followed by a transfer to ubiquinone at the Q<sub>0</sub> site. Cytochrome c then donates electrons to O<sub>2</sub> in complex IV, thus producing H<sub>2</sub>O [<xref ref-type="bibr" rid="bibr178-1753465812472940">Shimoda and Undem, 2010</xref>].</p>
<p>Under physiological conditions, approximately 2–3% of the oxygen consumed by mitochondria is incompletely reduced, and mitochondria therefore also produce <inline-formula id="inline-formula22-1753465812472940"><mml:math display="inline" id="math22-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> as a byproduct. Production of superoxide can occur at the complex I by auto-oxidation of flavins, with <inline-formula id="inline-formula23-1753465812472940"><mml:math display="inline" id="math23-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> formed being able to enter the matrix. Production of superoxide can also occur at the complex III at both Q0 and Qi sites, with <inline-formula id="inline-formula24-1753465812472940"><mml:math display="inline" id="math24-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> formed being able to enter either the matrix or the mitochondrial intermembrane space [<xref ref-type="bibr" rid="bibr156-1753465812472940">Perez-Vizcaino <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr185-1753465812472940">Stowe and Camara, 2009</xref>] (<xref ref-type="fig" rid="fig3-1753465812472940">Figure 3</xref>). In the matrix, <inline-formula id="inline-formula25-1753465812472940"><mml:math display="inline" id="math25-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is converted into H<sub>2</sub>O<sub>2</sub> by mitochondrial Mn SOD, and then to water by glutathione peroxidase [<xref ref-type="bibr" rid="bibr178-1753465812472940">Shimoda and Undem, 2010</xref>]. In the intermembrane space, <inline-formula id="inline-formula26-1753465812472940"><mml:math display="inline" id="math26-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> can be degraded by the cytosolic CuZn superoxide dismutase, can be scavenged by cytochrome c, or can enter the cytosol via voltage-dependent anion channels [<xref ref-type="bibr" rid="bibr77-1753465812472940">Han <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr209-1753465812472940">Waypa et al. 2002</xref>].</p>
<p>In the pulmonary vasculature, production of ROS by mitochondria is regulated by modulation ofmitochondria biogenesis and bioenergetics [<xref ref-type="bibr" rid="bibr51-1753465812472940">Erusalimsky and Moncada, 2007</xref>]. Modulation of these processes are dependent of multiple factors, including for example the availability of electron donors or the activity of cytokines and vasoactive mediators such as NO, angiotensin II or thromboxane A2 [<xref ref-type="bibr" rid="bibr5-1753465812472940">Bailey <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr165-1753465812472940">Rathore <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr208-1753465812472940">Waypa et al. 2010</xref>]. In addition, a ROS-induced ROS release mechanism may also occur in the pulmonary vasculature, with for example angiotensin II and hypoxia triggering an increased ROS production after Nox activation in PASMC, leading to a subsequent increase in mitochondrial ROS production [<xref ref-type="bibr" rid="bibr166-1753465812472940">Rathore <italic>et al.</italic> 2008</xref>]. Finally, the concentration of oxygen in pulmonary tissues is also particularly important in the modulation of ROS production by mitochondria, with ROS levels being elevated during hypoxia [<xref ref-type="bibr" rid="bibr185-1753465812472940">Stowe and Camara, 2009</xref>].</p>
</sec>
</sec>
<sec id="section12-1753465812472940">
<title>Antioxidant systems in the pulmonary vasculature</title>
<p>Enzymatic and nonenzymatic antioxidant systems are present in vascular tissues to protect against deleterious oxidative stress. Pulmonary vascular nonenzymatic antioxidants can scavenge HO<sup>●</sup> and other free radicals and include ascorbate, glutathione, bilirubin, tocopherols and uric acid [<xref ref-type="bibr" rid="bibr190-1753465812472940">Tajima <italic>et al.</italic> 2009</xref>]. Major pulmonary vascular enzymatic antioxidants include SOD, glutathione peroxidases, catalases, thioredoxin and peroxiredoxin [<xref ref-type="bibr" rid="bibr199-1753465812472940">Touyz and Briones, 2010</xref>]. The major vascular SOD is the extracellular SOD that is produced and secreted by vascular smooth muscle cells and then binds to glycosaminoglycans in the vascular extracellular matrix [<xref ref-type="bibr" rid="bibr68-1753465812472940">Gongora <italic>et al.</italic> 2006</xref>].</p>
</sec>
</sec>
<sec id="section13-1753465812472940">
<title>ROS-dependent signalling pathways in pulmonary vascular cells</title>
<p>ROS serve as important intracellular and intercellular messengers to regulate a variety of signalling pathways in pulmonary vascular cells. This redox signalling occurs mainly through reactions with protein residues, either with cysteine residues and formation of disulfide bridges, or through protein carbonylation [<xref ref-type="bibr" rid="bibr156-1753465812472940">Perez-Vizcaino <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr216-1753465812472940">Wong <italic>et al.</italic> 2008</xref>]. The main ROS targets in the pulmonary vasculature are described below and in <xref ref-type="fig" rid="fig4-1753465812472940">Figure 4</xref>.</p>
<fig id="fig4-1753465812472940" position="float">
<label>Figure 4.</label>
<caption>
<p>Redox-sensitive signalling pathways in pulmonary vascular cells and roles of ROS in pulmonary hypertension.</p>
<p>Increased ROS production in the pulmonary vasculature influences redox-sensitive signalling pathways in pulmonary vascular cells, leading to activation of redox-sensitive transcription factors and increased expression of many proteins involved in pulmonary vascular remodelling, inflammation and altered reactivity (both endothelium and smooth muscle dysfunctions).</p>
<p>EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; PDGF: platelet-derived growth factor; PDGFR: platelet-derived growth factor receptor; MAPK: mitogen-activated protein kinase; ROCK: Rho kinase; PKC: protein kinase C; JAK: janus kinase; Pyk: prolin-rich tyrosine kinase; PTP: protein tyrosine phosphatases; SHP-2: SH<sub>2</sub> domain-containing protein tyrosine phosphatase-2; PLD: phospholipase D; sGC: soluble guanylyl cyclase; MMPs: matrix metalloproteinases; COX: cyclo-oxygenases; PECAM: platelet/endothelial cell adhesion molecule; ICAM: intercellular adhesion molecule; VCAM: vascular cell adhesion molecule; HIF: hypoxia inducible factor; Egr-1: early growth response-1 transcription factor; STAT: signal transducer and activator of transcription; NF-κB: nuclear factor-κB; AP-1: activator protein-1; TGF-β1: transforming growth factor-β1; FGF-2: fibroblast growth factor-2; VEGF: vascular endothelial growth factor; TNF-α: tumor necrosis factor-α; IL: interleukin; eNOS: endothelial nitric oxide synthase; TRP: transient receptor potential channels; K<sub>ATP</sub>: ATP-sensitive potassium channels; K<sub>Ca</sub>: calcium-activated potassium channels; K<sub>v</sub>: voltage-gated potassium channels.</p>
</caption>
<graphic xlink:href="10.1177_1753465812472940-fig4.tif"/>
</fig>
<sec id="section14-1753465812472940">
<title>NO/guanylyl cyclase pathway</title>
<p>When superoxide production is increased, it can rapidly interact with NO and therefore attenuate its capacity to stimulate soluble guanylyl cyclase (sGC) in the systemic and pulmonary vasculatures [<xref ref-type="bibr" rid="bibr156-1753465812472940">Perez-Vizcaino <italic>et al.</italic> 2010</xref>]. Moreover, oxidative stress can oxidize the ferrous (Fe<sup>2+</sup>)–heme and thiol sites on sGC which control its activation by NO, and therefore contribute to decreased cGMP production and smooth muscle relaxation [<xref ref-type="bibr" rid="bibr215-1753465812472940">Wolin <italic>et al.</italic> 2010</xref>].</p>
<p>In addition, recent data obtained in our group show that ROS production in PASMC reduces endothelial NO-dependent control of pulmonary vasoreactivity, by targeting PAEC via myoendothelial gap junctions [<xref ref-type="bibr" rid="bibr12-1753465812472940">Billaud <italic>et al.</italic> 2009</xref>]. This is the first direct evidence of a smooth muscle negative feedback on NO-dependent endothelial vasodilatation, through <inline-formula id="inline-formula27-1753465812472940"><mml:math display="inline" id="math27-1753465812472940"><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mtext>●</mml:mtext></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> generation and decreased NO-induced cGMP production [<xref ref-type="bibr" rid="bibr12-1753465812472940">Billaud <italic>et al.</italic> 2009</xref>].</p>
</sec>
<sec id="section15-1753465812472940">
<title>Redox-sensitive enzymes</title>
<sec id="section16-1753465812472940">
<title>Receptor and nonreceptor tyrosine kinases</title>
<p>Classical activation of growth factor receptors by their agonist can be redox sensitive. For example, activation of its receptor by the platelet-derived growth factor (PDGF) is ROS-dependent [<xref ref-type="bibr" rid="bibr188-1753465812472940">Sundaresan <italic>et al.</italic> 1995</xref>]. In addition, many studies have also focused on transactivation of growth factor receptors, which is a way of activating the receptor tyrosine kinase in the absence of any extracellular agonist [<xref ref-type="bibr" rid="bibr105-1753465812472940">Knock and Ward, 2011</xref>]. This mechanism has been evidenced in particular in vascular smooth muscle cells for the epidermal growth factor receptor (EGFR) whose activation is induced by hydrogen peroxide or peroxynitrites in the absence of EGF [<xref ref-type="bibr" rid="bibr105-1753465812472940">Knock and Ward, 2011</xref>; <xref ref-type="bibr" rid="bibr204-1753465812472940">Ushio-Fukai <italic>et al.</italic> 2001</xref>]. Although these mechanisms have been evidenced in systemic vessels only, growth factors such as EGF or PDGF play an important role in particular in vascular remodelling observed in pulmonary arteries [<xref ref-type="bibr" rid="bibr193-1753465812472940">Thomas, 2010</xref>]. Such ROS-dependent mechanism may also occur in the pulmonary vasculature and may therefore contribute to PH pathophysiology.</p>
<p>Among nonreceptor tyrosine kinases, the src family is of particular interest in the pulmonary vasculature [<xref ref-type="bibr" rid="bibr105-1753465812472940">Knock and Ward, 2011</xref>]. Indeed, activation of Src kinase, in relation to activation of transcription factors such as the signal transducer and activator of transcription (STAT) 3 and the nuclear factor of activated T cells (NFAT), seems to play a pathophysiological role in PH [<xref ref-type="bibr" rid="bibr36-1753465812472940">Courboulin <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr153-1753465812472940">Paulin <italic>et al.</italic> 2011</xref>]. Since Src kinases have been implicated in regulation of hypoxia-induced contraction of pulmonary arteries [<xref ref-type="bibr" rid="bibr104-1753465812472940">Knock <italic>et al.</italic> 2008</xref>], and since this mechanism seems to be, at least in part, mediated by ROS generation [<xref ref-type="bibr" rid="bibr104-1753465812472940">Knock <italic>et al.</italic> 2008</xref>], the src kinase family may play a pivotal role in ROS-dependent signalling pathways in the pulmonary vasculature [<xref ref-type="bibr" rid="bibr71-1753465812472940">Griendling <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr105-1753465812472940">Knock and Ward, 2011</xref>], in both smooth muscle and endothelial cells. In the latter, the stimulatory effect of hydrogen peroxide on eNOS activity is src-dependent [<xref ref-type="bibr" rid="bibr163-1753465812472940">Rafikov <italic>et al.</italic> 2011</xref>].</p>
</sec>
<sec id="section17-1753465812472940">
<title>Protein tyrosine phosphatases</title>
<p>Protein tyrosine phosphorylation is one of the major post-transcriptional mechanisms and plays a critical role in many cell functions such as for example proliferation, differentiation and migration. The level of tyrosine phosphorylation is tightly regulated with a balance between protein tyrosine kinases (PTK) and protein tyrosine phosphatases (PTP) [<xref ref-type="bibr" rid="bibr148-1753465812472940">Paravicini and Touyz, 2006</xref>]. All PTP possess a reactive and redox-regulated cysteine, necessary for protein dephosphorylation. ROS-induced oxidation of this cysteine residue renders PTP totally inactive [<xref ref-type="bibr" rid="bibr195-1753465812472940">Tonks, 2005</xref>]. In particular, studies have shown ability of hydrogen peroxide, superoxide and peroxynitrites to inhibit PTP rapidly and irreversibly [<xref ref-type="bibr" rid="bibr112-1753465812472940">Lee and Esselman, 2002</xref>; <xref ref-type="bibr" rid="bibr148-1753465812472940">Paravicini and Touyz, 2006</xref>]. Since a role of PTP inhibition has recently been shown in PH, in particular in signalling pathways activated by growth factors such as PDGF [<xref ref-type="bibr" rid="bibr191-1753465812472940">ten Freyhaus <italic>et al.</italic> 2011</xref>], redox-dependent inhibition of PTP by ROS might contribute to these mechanisms.</p>
</sec>
<sec id="section18-1753465812472940">
<title>Serine/threonine kinases</title>
<p>Mitogen-activated protein kinases (MAPK) are a family of serine/threonine kinases that control many cellular effects such a proliferation, survival, differentiation, apoptosis and stress signals [<xref ref-type="bibr" rid="bibr71-1753465812472940">Griendling <italic>et al.</italic> 2000</xref>]. Activation of MAPK depends on many upstream phosphorylations, leading to activation of multiple signalling pathways. MAPK kinase redox sensitivity has been known for a long time, since exogenous ROS such as hydrogen peroxide and superoxide are able to activate MAPK in endothelial [<xref ref-type="bibr" rid="bibr89-1753465812472940">Huot <italic>et al.</italic> 1997</xref>, <xref ref-type="bibr" rid="bibr90-1753465812472940">1998</xref>] and smooth muscle cells [<xref ref-type="bibr" rid="bibr202-1753465812472940">Ushio-Fukai <italic>et al.</italic> 1998</xref>; <xref ref-type="bibr" rid="bibr222-1753465812472940">Yoshizumi <italic>et al.</italic> 2000</xref>]. In the vasculature, all of the major MAPK (extracellular-regulated protein kinase or ERK, p38 and c-jun N-terminal kinase [JNK]) are activated by growth factors such as angiotensin II or PDGF [<xref ref-type="bibr" rid="bibr188-1753465812472940">Sundaresan <italic>et al.</italic> 1995</xref>; <xref ref-type="bibr" rid="bibr202-1753465812472940">Ushio-Fukai <italic>et al.</italic> 1998</xref>]. More recently, studies have shown that intracellular ROS, mainly derived from NADPH oxidases, are involved in these signalling pathways [<xref ref-type="bibr" rid="bibr128-1753465812472940">Meloche <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr197-1753465812472940">Torrecillas <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr206-1753465812472940">Viedt <italic>et al.</italic> 2000</xref>]. Less is known about redox-induced regulation of MAPK in the pulmonary vasculature. However, ROS have been shown to activate ERK and p38 pathways in PAEC [<xref ref-type="bibr" rid="bibr201-1753465812472940">Usatyuk <italic>et al.</italic> 2003</xref>]. Inversely, ROS synthesis in PAEC by NADPH oxidases is dependent upon activation of ERK and p38 pathways [<xref ref-type="bibr" rid="bibr149-1753465812472940">Parinandi <italic>et al.</italic> 2003</xref>]. These results therefore suggest an interrelation between ROS and MAPK in pulmonary endothelial cells after activation by growth factors.</p>
<p>Rho kinases (ROCK) are serine/threonine kinases involved in the regulation of vascular tone, and in the development of several cardiovascular diseases [<xref ref-type="bibr" rid="bibr156-1753465812472940">Perez-Vizcaino <italic>et al.</italic> 2010</xref>]. Two isoforms have been identified and named ROCK-1 and ROCK-2, and both are expressed in the vascular smooth muscle [<xref ref-type="bibr" rid="bibr120-1753465812472940">Loirand <italic>et al.</italic> 2006</xref>]. ROCKs are activated by the small G protein RhoA and then phosphorylate the myosin light chain phosphatase (MLCP), which becomes inactive. Myosin phosphorylation is therefore increased, thus increasing contraction of the smooth muscle, independently of any increase in cytosolic calcium concentrations, a mechanism termed calcium sensitization [<xref ref-type="bibr" rid="bibr170-1753465812472940">Resta <italic>et al.</italic> 2010</xref>]. Such calcium sensitization through activation of the RhoA/ROCK pathway may contribute to the smooth muscle dysfunction observed in PH [<xref ref-type="bibr" rid="bibr34-1753465812472940">Connolly and Aaronson, 2011</xref>; <xref ref-type="bibr" rid="bibr147-1753465812472940">Oka <italic>et al.</italic> 2008</xref>], and a relationship between ROS and the RhoA/ROCK pathway has been described in pulmonary arteries [<xref ref-type="bibr" rid="bibr34-1753465812472940">Connolly and Aaronson, 2011</xref>; <xref ref-type="bibr" rid="bibr147-1753465812472940">Oka <italic>et al.</italic> 2008</xref>]. Indeed, in chronic hypoxia, RhoA activity is enhanced and is related to increased ROS production [<xref ref-type="bibr" rid="bibr23-1753465812472940">Broughton <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr97-1753465812472940">Jernigan <italic>et al.</italic> 2008</xref>]. Moreover, a superoxide generator causes ROCK-2 translocation to the nucleus in rat pulmonary arteries and induces a vasoconstriction sensitive to a ROCK inhibitor [<xref ref-type="bibr" rid="bibr103-1753465812472940">Knock <italic>et al.</italic> 2009</xref>]. Hydrogen peroxide may also be able to increase RhoA activity in PAECs and PASMCs [<xref ref-type="bibr" rid="bibr31-1753465812472940">Chi <italic>et al.</italic> 2010</xref>] although controversial results have been observed in other studies [<xref ref-type="bibr" rid="bibr105-1753465812472940">Knock and Ward, 2011</xref>; <xref ref-type="bibr" rid="bibr156-1753465812472940">Perez-Vizcaino <italic>et al.</italic> 2010</xref>].</p>
<p>The protein kinase C family contains several isoforms belonging either to conventional PKC or cPKC (α, β1, β2 and γ), to novel PKC or nPKC (δ, ϵ, η, θ, υ, and µ) or to atypical PKC or aPKC (ζ and λ/ι) [<xref ref-type="bibr" rid="bibr171-1753465812472940">Reyland, 2009</xref>]. In pulmonary arteries, various PKC isoforms are expressed in fibroblasts, endothelial and smooth muscle cells [<xref ref-type="bibr" rid="bibr40-1753465812472940">Dempsey <italic>et al.</italic> 2007</xref>]. Hydrogen peroxide and peroxynitrites can activate PKC in PASMCs [<xref ref-type="bibr" rid="bibr27-1753465812472940">Chakraborti and Michael, 1993</xref>]. In addition, hydrogen-peroxide-induced calcium sensitization is associated with PKCα activation, and is blocked by PKC inhibitors [<xref ref-type="bibr" rid="bibr158-1753465812472940">Pourmahram <italic>et al.</italic> 2008</xref>]. Moreover, hypoxia-induced ROS production is PKC-dependent in PASMCs [<xref ref-type="bibr" rid="bibr166-1753465812472940">Rathore <italic>et al.</italic> 2008</xref>] and in PAECs [<xref ref-type="bibr" rid="bibr28-1753465812472940">Chatterjee <italic>et al.</italic> 2011</xref>]. These results therefore suggest a role of ROS in PKC-dependent signalling pathways in pulmonary vascular cells.</p>
<p>The serine/threonine kinase Akt, also called protein kinase B or PKB, is a downstream target of phosphatidylinositol-3 kinase, and plays a major role in various cellular processes, including cell proliferation and survival, as well as in protein synthesis [<xref ref-type="bibr" rid="bibr32-1753465812472940">Coffer <italic>et al.</italic> 1998</xref>]. A relation between Akt and ROS has been evidenced in systemic vascular smooth muscle cells from various origins, since exogenous hydrogen peroxide induces Akt activation in these cells [<xref ref-type="bibr" rid="bibr203-1753465812472940">Ushio-Fukai <italic>et al.</italic> 1999</xref>]. In addition, angiotensin-II-induced activation of Akt is inhibited by catalase, suggesting a role for ROS in agonist-induced Akt activation [<xref ref-type="bibr" rid="bibr203-1753465812472940">Ushio-Fukai <italic>et al.</italic> 1999</xref>]. In the pulmonary vasculature, ROS generation by NADPH oxidase in PASMC leads to redox-sensitive activation of Akt [<xref ref-type="bibr" rid="bibr47-1753465812472940">Djordjevic <italic>et al.</italic> 2005</xref>]. Moreover, in the same cells, expression of the fibroblast growth factor-2 (FGF-2) is mediated by an increase in superoxide levels via NADPH oxidase activation, a mechanism that is blocked by a pharmacological inhibitor of Akt [<xref ref-type="bibr" rid="bibr14-1753465812472940">Black <italic>et al.</italic> 2008</xref>]. In addition, chronic intermittent hypoxia causes PH and is associated with increased lung levels of NADPH oxidases as well as increased activity of PDGFR and Akt [<xref ref-type="bibr" rid="bibr142-1753465812472940">Nisbet <italic>et al.</italic> 2009</xref>]. These mechanisms are reduced in Nox2 knockout mice [<xref ref-type="bibr" rid="bibr142-1753465812472940">Nisbet <italic>et al.</italic> 2009</xref>], therefore suggesting a role for NADPH oxidase-derived ROS in Akt activation associated with PH.</p>
</sec>
<sec id="section19-1753465812472940">
<title>Other candidate enzymes</title>
<p>Many other enzymes appear to be redox sensitive and are activated by addition of exogenous ROS [<xref ref-type="bibr" rid="bibr71-1753465812472940">Griendling <italic>et al.</italic> 2000</xref>]. For example, phospholipase D is activated by hydrogen peroxide in endothelial cells[<xref ref-type="bibr" rid="bibr140-1753465812472940">Natarajan <italic>et al.</italic> 1993</xref>], and PDGF-induced activation of STAT 1 is inhibited by antioxidants [<xref ref-type="bibr" rid="bibr179-1753465812472940">Simon <italic>et al.</italic> 1998</xref>]. In addition, activation of many other kinases such as Fyn kinase, Proline-rich tyrosine kinase (Pyk) or JAK, seem to be ROS-dependent in vascular tissues from other origins than the lung and may therefore also contribute to the regulation of pulmonary vascular tone in physiological and pathophysiological conditions [<xref ref-type="bibr" rid="bibr105-1753465812472940">Knock and Ward, 2011</xref>].</p>
</sec>
</sec>
<sec id="section20-1753465812472940">
<title>Ion channels</title>
<p>Voltage-gated potassium channels (K<sub>v</sub>) play an important role in the regulation of pulmonary vascular tone, and their inhibition seems to be involved in PH pathophysiological mechanisms [<xref ref-type="bibr" rid="bibr137-1753465812472940">Moudgil <italic>et al.</italic> 2006</xref>]. Effects of ROS on K<sub>v</sub> channels have been evidenced in pulmonary arteries. Indeed, in PASMC, hypoxia induces ROS production and leads to inhibition of K<sub>v</sub> channels [<xref ref-type="bibr" rid="bibr16-1753465812472940">Bonnet and Archer, 2007</xref>]. Moreover, hydrogen peroxide homologues also block K<sub>v</sub> channel activity, whereas hypoxia-induced K<sub>v</sub> channel inhibition is prevented by catalase [<xref ref-type="bibr" rid="bibr33-1753465812472940">Cogolludo <italic>et al.</italic> 2006</xref>].</p>
<p>Transient receptor potential (TRP) channels are composed of several subfamilies and contribute to cation entry in pulmonary arteries [<xref ref-type="bibr" rid="bibr46-1753465812472940">Dietrich and Gudermann, 2011</xref>; <xref ref-type="bibr" rid="bibr74-1753465812472940">Guibert <italic>et al.</italic> 2011</xref>]. In particular, expression of TRP channel subtypes belonging to the canonical (TRPC), melastatin-related (TRPM) and vanilloid-related (TRPV) subfamilies have been identified in pulmonary arteries [<xref ref-type="bibr" rid="bibr220-1753465812472940">Yang <italic>et al.</italic> 2010</xref>]. Although direct evidence of TRP modulation by ROS in pulmonary arteries is lacking, ROS-induced regulation of TRP channels has been observed in other vascular tissues [<xref ref-type="bibr" rid="bibr182-1753465812472940">Song <italic>et al.</italic> 2011</xref>], and may therefore contribute to regulation of calcium entry, in particular in PASMC.</p>
</sec>
<sec id="section21-1753465812472940">
<title>Redox-sensitive gene expression</title>
<p>Many cardiovascular genes are redox sensitive, with ROS regulating expression of adhesion molecules, chemotactic factors, antioxidant enzymes and vasoactive substances [<xref ref-type="bibr" rid="bibr71-1753465812472940">Griendling <italic>et al.</italic> 2000</xref>]. This regulation occurs at various levels. Redox sensitivity of some genes can lead to activation of their transcription by ROS-dependent signalling pathways [<xref ref-type="bibr" rid="bibr219-1753465812472940">Wung <italic>et al.</italic> 1999</xref>]. ROS can also modify the activity of specific transcription factors, modulating their turnover, expression, translocation or affinity to their cognate DNA-binding sites. This has been shown in systemic vascular cells in particular for the nuclear factor (NF)-κB [<xref ref-type="bibr" rid="bibr135-1753465812472940">Morgan and Liu, 2011</xref>] and the activator protein-1 (AP-1) [<xref ref-type="bibr" rid="bibr8-1753465812472940">Barchowsky <italic>et al.</italic> 1995</xref>; <xref ref-type="bibr" rid="bibr169-1753465812472940">Remacle <italic>et al.</italic> 1995</xref>], but also for the hypoxia-inducible factor (HIF)-1, known to play an important role in hypoxia-induced PH [<xref ref-type="bibr" rid="bibr87-1753465812472940">Huang <italic>et al.</italic> 1996</xref>].</p>
<p>Most of the redox-sensitive genes identified so far are responsive to externally applied oxidant stress, but some of them have also been demonstrated to be downstream of an endogenous source of ROS, such as genes for angiotensin II, PDGF or tumor necrosis factor-α (TNF-α) [<xref ref-type="bibr" rid="bibr71-1753465812472940">Griendling <italic>et al.</italic> 2000</xref>], or genes for many other inflammatory cytokines and adhesion molecules [<xref ref-type="bibr" rid="bibr148-1753465812472940">Paravicini and Touyz, 2006</xref>]. Since all of these molecules play an important role in PH development and persistence, these data suggest that regulation of gene expression by oxidative stress may be important in pulmonary vascular cells.</p>
</sec>
</sec>
<sec id="section22-1753465812472940">
<title>Important role of ROS in the pathogenesis of PH</title>
<sec id="section23-1753465812472940">
<title>Sources of ROS in PH</title>
<p>Oxidative stress in the pulmonary vasculature has been evidenced in many PH animal models. In chronic hypoxia-induced PH, an increase in ROS production has been shown in pulmonary arteries [<xref ref-type="bibr" rid="bibr57-1753465812472940">Fresquet <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr85-1753465812472940">Hoshikawa <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr94-1753465812472940">Jankov <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr119-1753465812472940">Liu <italic>et al.</italic> 2006</xref>]. In addition, many of the pathological changes in the pulmonary vasculature observed in this model can be reversed by the administration of antioxidants [<xref ref-type="bibr" rid="bibr50-1753465812472940">Elmedal <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr85-1753465812472940">Hoshikawa <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr107-1753465812472940">Lai <italic>et al.</italic> 1998</xref>]. In the rat model of PH induced by monocrotaline (an alkaloid extracted from the plant <italic>Crotalaria spectabilis</italic> that, once metabolized in the liver, induces pulmonary endothelial cell necrosis and leads to severe PH), elevated levels of superoxide have also been reported in pulmonary arteries [<xref ref-type="bibr" rid="bibr98-1753465812472940">Kamezaki <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr125-1753465812472940">Mathew <italic>et al.</italic> 2002</xref>]. In this model as well, antioxidant therapies attenuate PH development and decrease right ventricular hypertrophy [<xref ref-type="bibr" rid="bibr98-1753465812472940">Kamezaki <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr167-1753465812472940">Redout <italic>et al.</italic> 2010</xref>]. In addition, elevated superoxide levels have been reported in other PH models [<xref ref-type="bibr" rid="bibr22-1753465812472940">Brennan <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr73-1753465812472940">Grobe <italic>et al.</italic> 2006</xref>]. These results are in accordance with data observed in humans where increased ROS levels associated with decreased activity of antioxidant enzymes such as Mn SOD have been reported in the lungs of PH patients [<xref ref-type="bibr" rid="bibr19-1753465812472940">Bowers <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr39-1753465812472940">Demarco <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr183-1753465812472940">Spiekermann <italic>et al.</italic> 2009</xref>]. These data therefore suggest that chronic oxidative stress is present in lungs of PH patients.</p>
<p>In accordance with increased ROS levels detected in the pulmonary vasculature during PH, expression and/or activity of various sources of ROS is increased in pulmonary arteries. Several studies have reported an important role of NADPH oxidases, and in particular of several Nox subunits, in various PH animal models [<xref ref-type="bibr" rid="bibr41-1753465812472940">Dennis <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr73-1753465812472940">Grobe <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr168-1753465812472940">Redout <italic>et al.</italic> 2007</xref>]. Indeed, Nox2 knockout mice fail to develop hypoxia-induced PH [<xref ref-type="bibr" rid="bibr119-1753465812472940">Liu <italic>et al.</italic> 2006</xref>], and these mice were in particular protected against the development of endothelial dysfunction in intrapulmonary arteries [<xref ref-type="bibr" rid="bibr57-1753465812472940">Fresquet <italic>et al.</italic> 2006</xref>]. Hypoxia-induced PH in mice was also associated with increased lung levels of Nox4 [<xref ref-type="bibr" rid="bibr132-1753465812472940">Mittal <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr142-1753465812472940">Nisbet <italic>et al.</italic> 2009</xref>]. In lungs from patients with idiopathic pulmonary arterial hypertension, expression levels of Nox4 were upregulated [<xref ref-type="bibr" rid="bibr132-1753465812472940">Mittal <italic>et al.</italic> 2007</xref>]. <italic>In vitro</italic>, a significant increase of Nox4 expression has been observed under hypoxic conditions in human pulmonary artery adventitial fibroblasts [<xref ref-type="bibr" rid="bibr118-1753465812472940">Li <italic>et al.</italic> 2008</xref>] and in PASMC [<xref ref-type="bibr" rid="bibr132-1753465812472940">Mittal <italic>et al.</italic> 2007</xref>]. Nox4 expression was further increased under hypoxic conditions in pulmonary artery adventitial fibroblasts isolated from the lungs of patients with idiopathic pulmonary arterial hypertension compared with control donors [<xref ref-type="bibr" rid="bibr118-1753465812472940">Li <italic>et al.</italic> 2008</xref>]. Altogether, these results therefore suggest a preponderant role for NAPDH oxidase containing Nox2 and/or Nox4 in oxidative stress in PH.</p>
<p>Some data also provide evidence of eNOS uncoupling in pulmonary arteries, contributing to the generation of elevated levels of ROS during PH. Data obtained in mutant models underline that local BH<sub>4</sub> availability is crucial in maintaining pulmonary vascular homeostasis and plays a pivotal role in the pathogenesis of PH [<xref ref-type="bibr" rid="bibr100-1753465812472940">Khoo <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr139-1753465812472940">Nandi <italic>et al.</italic> 2005</xref>]. Indeed, increased BH<sub>4</sub> synthesis prevents PH development. Conversely, BH<sub>4</sub> deficiency elevates pulmonary vascular tone by decreasing eNOS activity and NO bioactivity, and promotes pulmonary vascular remodelling, PH and right ventricular hypertrophy [<xref ref-type="bibr" rid="bibr100-1753465812472940">Khoo <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr139-1753465812472940">Nandi <italic>et al.</italic> 2005</xref>]. These data were obtained in genetically modified mice models, in which tissue BH<sub>4</sub> levels are low because of reduced expression of GTPCH-1, or in which endothelial BH<sub>4</sub> synthesis is augmented by targeted overexpression of GTPCH-1. However, only few studies have investigated whether alterations of biopterin metabolism and eNOS uncoupling occur in pathophysiological relevant PH models: in lamb models of persistent PH of the newborn, increases in oxidative stress due to uncoupled eNOS and elevated levels of BH<sub>2</sub> likely contribute to impaired NO-dependent pulmonary vasodilation [<xref ref-type="bibr" rid="bibr73-1753465812472940">Grobe <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr106-1753465812472940">Konduri <italic>et al.</italic> 2007</xref>]. Other studies also provide evidence of eNOS uncoupling in pulmonary arteries, contributing to generate elevated levels of ROS during PH [<xref ref-type="bibr" rid="bibr66-1753465812472940">Gielis <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr96-1753465812472940">Jerkic <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr106-1753465812472940">Konduri <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr108-1753465812472940">Lakshminrusimha <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr196-1753465812472940">Toporsian <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr218-1753465812472940">Wunderlich <italic>et al.</italic> 2008</xref>].</p>
<p>Altered expression and/or activity of other ROS sources in pulmonary arteries have also been reported. For example, activity of XO is increased, leading to elevated ROS levels <italic>in vitro</italic> in cultured pulmonary vascular cells [<xref ref-type="bibr" rid="bibr192-1753465812472940">Terada <italic>et al.</italic> 1992</xref>], and <italic>in vivo</italic> as well with increased nitrotyrosine formation in pulmonary arteries [<xref ref-type="bibr" rid="bibr94-1753465812472940">Jankov <italic>et al.</italic> 2008</xref>].</p>
</sec>
<sec id="section24-1753465812472940">
<title>ROS and altered pulmonary vascular reactivity</title>
<p>Many studies have shown evidence of a role of ROS in altered pulmonary vascular reactivity observed in PH (<xref ref-type="fig" rid="fig4-1753465812472940">Figure 4</xref>). Indeed, both increased reactivity to contractile agents and endothelial dysfunction can be prevented or reversed by antioxidant treatments [<xref ref-type="bibr" rid="bibr50-1753465812472940">Elmedal <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr107-1753465812472940">Lai <italic>et al.</italic> 1998</xref>; <xref ref-type="bibr" rid="bibr119-1753465812472940">Liu <italic>et al.</italic> 2006</xref>]. An important role for NADPH oxidase-derived ROS has been evidenced in some studies. Indeed, hypoxia-induced amplification of the responses of pulmonary arteries to various vasoconstrictors is decreased in Nox2 knockout mice [<xref ref-type="bibr" rid="bibr119-1753465812472940">Liu <italic>et al.</italic> 2006</xref>]. As demonstrated by our group, these Nox2 knockout mice are also protected against development of endothelial dysfunction in intrapulmonary arteries [<xref ref-type="bibr" rid="bibr57-1753465812472940">Fresquet <italic>et al.</italic> 2006</xref>]. Therefore, these data show a role for Nox2-derived ROS in exacerbated vasoconstriction and endothelial dysfunction induced by chronic hypoxia in pulmonary arteries. Nox4 also plays a role in hypoxia-induced contraction of mice [<xref ref-type="bibr" rid="bibr166-1753465812472940">Rathore <italic>et al.</italic> 2008</xref>] or of bovine pulmonary arteries [<xref ref-type="bibr" rid="bibr1-1753465812472940">Ahmad <italic>et al.</italic> 2010</xref>]. Indeed, Nox4 is activated by hypoxia and increases intracellular ROS and calcium levels to participate to PASMC contraction [<xref ref-type="bibr" rid="bibr166-1753465812472940">Rathore <italic>et al.</italic> 2008</xref>].</p>
<p>Data obtained in our group reveal an endothelial dysfunction occurring within the intrapulmonary arteries of hypoxic mice, despite marked upregulation of eNOS expression (<xref ref-type="fig" rid="fig5-1753465812472940">Figure 5</xref>). Moreover, these data also show that, even though hypoxic Nox2 knockout mice did not develop endothelial dysfunction, endothelium-dependent relaxation to acetylcholine was not improved in hypoxic wild-type mice in the presence of ROS scavengers such as cell-permeant SOD or catalase [<xref ref-type="bibr" rid="bibr57-1753465812472940">Fresquet <italic>et al.</italic> 2006</xref>] (<xref ref-type="fig" rid="fig5-1753465812472940">Figure 5</xref>). These results therefore suggest that impairment of endothelial NO-dependent relaxation in pulmonary arteries from hypoxic mice is not due to inactivation of NO by ROS. This is further supported by the finding that β<sub>2</sub>-adrenergic receptor-induced relaxation is not altered in intrapulmonary arteries from hypoxic mice, even if this relaxation, similarly to the one induced by acetylcholine, is mediated by endothelial NO [<xref ref-type="bibr" rid="bibr109-1753465812472940">Leblais <italic>et al.</italic> 2008</xref>] (<xref ref-type="fig" rid="fig5-1753465812472940">Figure 5</xref>). Our data even show that relaxation induced through activation of β<sub>2</sub>-adrenergic receptors or through the exogenous NO donor sodium nitroprusside may rather be increased in intrapulmonary arteries from hypoxic mice [<xref ref-type="bibr" rid="bibr109-1753465812472940">Leblais <italic>et al.</italic> 2008</xref>] (<xref ref-type="fig" rid="fig5-1753465812472940">Figure 5</xref>). Altogether, these data indicate that NADPH-oxidase derived ROS may act as a trigger rather than a direct mediator of endothelial dysfunction in intrapulmonary arteries during hypoxic PH. Moreover, since activation of pulmonary β<sub>2</sub>-adrenergic and muscarinic receptors both lead to eNOS activation, but through activation of different signalling pathways [<xref ref-type="bibr" rid="bibr6-1753465812472940">Banquet <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr109-1753465812472940">Leblais <italic>et al.</italic> 2008</xref>], mechanisms underlying eNOS activation might therefore be key determinants of pulmonary endothelial dysfunction occurring in PH.</p>
<fig id="fig5-1753465812472940" position="float">
<label>Figure 5.</label>
<caption>
<p>ROS are triggers rather than direct mediators of endothelial dysfunction in hypoxic pulmonary hypertension.</p>
<p>(A) Effect of chronic hypoxia on endothelial nitric oxide synthase (eNOS) expression in lungs from mice exposed to normoxia (NX) or 21 days of hypoxia (HX 21d). Results are expressed as mean ± SEM of quantified data normalised to β-actin and blots are representative of <italic>n</italic> = 5 independent experiments. ***<italic>p</italic> &lt; 0.001 compared with NX. These results show that eNOS expression is significantly increased in mice total lungs after chronic hypoxia. (B) Relaxant responses to acetylcholine (ACh, 10 µM), to the exogenous nitric oxide donor sodium nitroprusside (SNP, 1 µM) or to the β<sub>2</sub>-adernergic receptor agonist procaterol (Proc, 0.1 µM) in intrapulmonary arteries from mice exposed to normoxia (NX, white bars) or 21 days of hypoxia (HX 21d, black bars). Relaxant responses to ACh were also evaluated in the presence of ROS scavengers: either catalase (Cat, 250 U/ml) or the cell-permeant superoxide dismutase (SOD, 200 U/ml). Results are expressed as mean ± SEM of <italic>n</italic> = 5–12 independent experiments. NS: not significant, **<italic>p</italic> &lt; 0.01 and ****<italic>p</italic> &lt; 0.001. These results show that endothelium-dependent relaxation to acetylcholine is altered by chronic hypoxia, but this effect is not modified in the presence of ROS scavengers such as catalase or SOD. Conversely, endothelium-dependent relaxation to procaterol is rather increased by chronic hypoxia, and so is the relaxation induced by the exogenous NO donor SNP. Altogether, these results show that, although eNOS expression is increased after chronic hypoxia, acetylcholine-induced relaxation is impaired in intrapulmonary arteries. This impairment is not due to NO inactivation by ROS. Moreover, such impairment is not observed after chronic hypoxia when NO-dependent relaxation of intrapulmonary arteries is induced by other stimuli through activation of other signalling pathways. Mechanisms underlying eNOS activation may therefore be of major importance in pulmonary endothelial dysfunction induced by chronic hypoxia.</p>
</caption>
<graphic xlink:href="10.1177_1753465812472940-fig5.tif"/>
</fig>
<p>In addition to endothelial dysfunction, pulmonary arteries often exhibit hyperreactivity to contractile agents in PH. Isoprostanes (products from ROS-mediated peroxidation of fatty acids) may participate in these vasomotor alterations. Indeed, as recently demonstrated by our group, release of isoprostanes by pulmonary arteries is increased during chronic hypoxia [<xref ref-type="bibr" rid="bibr38-1753465812472940">Delannoy <italic>et al.</italic> 2010</xref>]. Moreover, pulmonary arterial hyperreactivity to phenylephrine in hypoxic mice is decreased by catalase and by TP receptor antagonists. These results therefore show that ROS contribute to pulmonary arterial hyperreactivity to contractile agents in PH via isoprostane production and further activation of TP receptors [<xref ref-type="bibr" rid="bibr38-1753465812472940">Delannoy <italic>et al.</italic> 2010</xref>]. Such mechanism has also been recently observed in newborn piglets with chronic hypoxia-induced PH [<xref ref-type="bibr" rid="bibr53-1753465812472940">Fike <italic>et al.</italic> 2011</xref>].</p>
</sec>
<sec id="section25-1753465812472940">
<title>ROS and pulmonary vascular remodelling</title>
<p>Studies have evidenced a role of ROS in pulmonary vascular remodelling observed in PH, with in particular an important role of NADPH oxidase-derived ROS (<xref ref-type="fig" rid="fig4-1753465812472940">Figure 4</xref>). Indeed, Nox2 knockout mice are protected against development of vascular remodelling in chronic hypoxia-induced PH [<xref ref-type="bibr" rid="bibr119-1753465812472940">Liu <italic>et al.</italic> 2006</xref>], and Nox4 participates in hypoxia-induced pulmonary vascular remodelling [<xref ref-type="bibr" rid="bibr132-1753465812472940">Mittal <italic>et al.</italic> 2007</xref>]. ROS generation from other sources may also contribute to pulmonary vascular remodelling. For example, the increased pulmonary vascular remodelling in a mouse model of familial PH is associated with eNOS-dependent ROS production [<xref ref-type="bibr" rid="bibr96-1753465812472940">Jerkic <italic>et al.</italic> 2011</xref>].</p>
<p>Mechanisms activated by ROS and participating in pulmonary vascular remodelling are various and involve all pulmonary vascular cell types [<xref ref-type="bibr" rid="bibr56-1753465812472940">Frazziano <italic>et al.</italic> 2012</xref>]. Medial thickening observed in pulmonary arterial remodelling is characterized in particular by increased proliferation and decreased apoptosis of PASMCs [<xref ref-type="bibr" rid="bibr82-1753465812472940">Hassoun <italic>et al.</italic> 2009</xref>]. PASMC proliferation can be directly stimulated by ROS such as superoxide and hydrogen peroxide [<xref ref-type="bibr" rid="bibr212-1753465812472940">Wedgwood <italic>et al.</italic> 2001</xref>]. Conversely, antioxidants such as superoxide dismutase or catalase can inhibit proliferation of PASMC, and even induce their apoptosis in the long term [<xref ref-type="bibr" rid="bibr210-1753465812472940">Wedgwood and Black, 2003</xref>, <xref ref-type="bibr" rid="bibr211-1753465812472940">2004</xref>; <xref ref-type="bibr" rid="bibr212-1753465812472940">Wedgwood <italic>et al.</italic> 2001</xref>]. In addition, ROS contribute to PASMC proliferation triggered by hypoxia, by directly involving activation of Nox4 [<xref ref-type="bibr" rid="bibr132-1753465812472940">Mittal <italic>et al.</italic> 2007</xref>]. Hypoxia-induced ROS generation in PASMC also contributes to increased expression and activity of the hypoxia-inducible factors (HIF)-1αand HIF-2α, involved in PASMC proliferation [<xref ref-type="bibr" rid="bibr43-1753465812472940">Diebold <italic>et al.</italic> 2010a</xref>, <xref ref-type="bibr" rid="bibr45-1753465812472940">2010c</xref>]. Interestingly, activation of HIF-1α by hypoxia in PASMC increases ROS production in these cells through activation of Nox4 [<xref ref-type="bibr" rid="bibr45-1753465812472940">Diebold <italic>et al.</italic> 2010c</xref>] and Rac-1 transcription [<xref ref-type="bibr" rid="bibr44-1753465812472940">Diebold <italic>et al.</italic> 2010b</xref>; <xref ref-type="bibr" rid="bibr152-1753465812472940">Patil <italic>et al.</italic> 2004</xref>]. These data therefore suggest the existence of a positive feedback loop that may contribute to increase PASMC proliferation in hypoxic conditions. This positive feedback loop has also been demonstrated for HIF-2α in PASMC [<xref ref-type="bibr" rid="bibr43-1753465812472940">Diebold <italic>et al.</italic> 2010a</xref>]. Finally, ROS-induced activation of HIF-1α in PASMC also increases expression of several factors, such as FGF-2, that can exert an autocrine proliferative effect and contribute to increased PASMC proliferation in hypoxic conditions [<xref ref-type="bibr" rid="bibr14-1753465812472940">Black <italic>et al.</italic> 2008</xref>]. Moreover, hypoxia-induced PASMC proliferation also involves increased mitochondrial ROS production with opening of K<sub>ATP</sub> channels and mitochondrial depolarization [<xref ref-type="bibr" rid="bibr86-1753465812472940">Hu <italic>et al.</italic> 2010</xref>]. Finally, ROS can activate other transcription factors, such as for example the redox-sensitive transcription factor early growth response-1 (Egr-1), involved in hypoxia-induced PASMC proliferation [<xref ref-type="bibr" rid="bibr81-1753465812472940">Hartney <italic>et al.</italic> 2011</xref>]. ROS also contribute to PASMC proliferation induced by several vasoactive factors. For example, endothelin-1 stimulates PASMC proliferation via NADPH oxidase-catalysed ROS production [<xref ref-type="bibr" rid="bibr212-1753465812472940">Wedgwood <italic>et al.</italic> 2001</xref>]. Activation of NADPH oxidase by serotonin stimulates the proliferation of bovine PASMC via a pathway involving the MAP kinases ERK1/2 [<xref ref-type="bibr" rid="bibr114-1753465812472940">Lee <italic>et al.</italic> 1999</xref>, <xref ref-type="bibr" rid="bibr113-1753465812472940">2001</xref>]. Several growth factors have also been shown to activate NADPH oxidase in vascular smooth muscle cells, including angiotensin II [<xref ref-type="bibr" rid="bibr70-1753465812472940">Griendling <italic>et al.</italic> 1994</xref>] and PDGF [<xref ref-type="bibr" rid="bibr123-1753465812472940">Marumo <italic>et al.</italic> 1997</xref>]. In PASMCs, the transforming growth factor-β1 (TGF-β1) activates Nox4 and increases ROS production that contributes to TGF-β1-induced cell proliferation [<xref ref-type="bibr" rid="bibr92-1753465812472940">Ismail <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr186-1753465812472940">Sturrock <italic>et al.</italic> 2006</xref>]. TGF-β1-induced ROS production in PASMC also contributes to upregulated expression of other growth factors, such as the vascular endothelium growth factor (VEGF) [<xref ref-type="bibr" rid="bibr124-1753465812472940">Mata-Greenwood <italic>et al.</italic> 2005</xref>]. These results therefore suggest that ROS-mediated signalling pathways contribute to increase PASMC proliferation stimulated by various contractile and growth factors whose expression is increased in PH. As described recently, iron may play an important role in these ROS-dependent signalling pathways for PASMC growth [<xref ref-type="bibr" rid="bibr217-1753465812472940">Wong <italic>et al.</italic> 2012</xref>].</p>
<p>ROS may also be involved in pulmonary vascular remodelling through participating to the excessive proliferation of endothelial cells. Indeed, ROS directly stimulates PAEC proliferation [<xref ref-type="bibr" rid="bibr24-1753465812472940">Browning <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr131-1753465812472940">Milovanova <italic>et al.</italic> 2004</xref>, <xref ref-type="bibr" rid="bibr130-1753465812472940">2006</xref>], and triggers angiogenesis [<xref ref-type="bibr" rid="bibr141-1753465812472940">Nijmeh <italic>et al.</italic> 2010</xref>]. Conversely, antioxidants can inhibit PAEC proliferation [<xref ref-type="bibr" rid="bibr78-1753465812472940">Han <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr130-1753465812472940">Milovanova <italic>et al.</italic> 2006</xref>]. ROS may also contribute to PAEC survival induced by other factors, such as the endogenous cytochrome P-450 product 20-hydroxyeicosatetraenoic acid (20-HETE) [<xref ref-type="bibr" rid="bibr42-1753465812472940">Dhanasekaran <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr127-1753465812472940">Medhora <italic>et al.</italic> 2008</xref>]. Finally, oxidative stress can also activate HIF-1α in PAEC and therefore increase expression of factors such as PDGF that participate in pulmonary vascular remodelling [<xref ref-type="bibr" rid="bibr129-1753465812472940">Mermis <italic>et al.</italic> 2011</xref>].</p>
<p>ROS have been shown to participate to many signalling pathways in adventitial fibroblasts from various origins [<xref ref-type="bibr" rid="bibr83-1753465812472940">Haurani and Pagano, 2007</xref>]. The role of the adventitial layer in vascular inflammation and remodelling is now largely studied, in particular in PH [<xref ref-type="bibr" rid="bibr184-1753465812472940">Stenmark <italic>et al.</italic> 2012</xref>]. ROS stimulate proliferation and inhibit apoptosis of pulmonary artery adventitial fibroblasts [<xref ref-type="bibr" rid="bibr118-1753465812472940">Li <italic>et al.</italic> 2008</xref>], and may therefore contribute to adventitial remodelling observed in PH [<xref ref-type="bibr" rid="bibr184-1753465812472940">Stenmark <italic>et al.</italic> 2012</xref>].</p>
<p>Finally, modulation of the extracellular matrix by matrix metalloproteinases (MMPs) is also an important component in vascular remodelling of the pulmonary vasculature [<xref ref-type="bibr" rid="bibr29-1753465812472940">Chelladurai <italic>et al.</italic> 2012</xref>]. MMPs are a family of enzymes capable of degrading components of the extracellular matrix, and their activity is tightly regulated at transcriptional and protein synthesis levels. MMP-2 and MMP-9 expression and activity are increased in PH [<xref ref-type="bibr" rid="bibr26-1753465812472940">Cantini-Salignac <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr59-1753465812472940">Frisdal <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr116-1753465812472940">Lepetit <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr200-1753465812472940">Umar <italic>et al.</italic> 2007</xref>], and MMP-9 overexpression in transgenic mice augments PH [<xref ref-type="bibr" rid="bibr65-1753465812472940">George and D’Armiento, 2011</xref>]. NAPDH oxidase-dependent generation of ROS in PAEC leads to MMP activation [<xref ref-type="bibr" rid="bibr35-1753465812472940">Cook-Mills, 2006</xref>]. Moreover, a role for ROS has recently been established in right ventricular failure observed in PH, through induction of MMP activity [<xref ref-type="bibr" rid="bibr160-1753465812472940">Qipshidze <italic>et al.</italic> 2011</xref>]. These results therefore suggest that redox-sensitive mechanisms occur in the pulmonary vasculature for MMPs, and may contribute to pulmonary arterial remodelling.</p>
</sec>
<sec id="section26-1753465812472940">
<title>ROS and pulmonary vascular inflammation</title>
<p>Inflammation is a common feature in remodelling vessels in PH, characterized by an accumulation of perivascular inflammatory cells, including macrophages, dendritic cells, T and B lymphocytes, and mast cells, together with elevated circulating levels of various cytokines and chemokines [<xref ref-type="bibr" rid="bibr159-1753465812472940">Price <italic>et al.</italic> 2012</xref>]. In the lung, ROS activate redox-sensitive transcription factors such as AP-1, HIF-1 of NF-κB to initiate inflammatory responses [<xref ref-type="bibr" rid="bibr110-1753465812472940">Lee and Yang, 2012</xref>; <xref ref-type="bibr" rid="bibr150-1753465812472940">Park <italic>et al.</italic> 2009</xref>]. For example, in response to oxidative stress, lung cells release pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-6, IL-8 and TNF-α [<xref ref-type="bibr" rid="bibr164-1753465812472940">Rahman and MacNee, 2000</xref>]. Moreover, expression of many inflammatory target proteins triggered by pro-inflammatory cytokines such as IL-1β or TNF-α occurs through increased ROS production [<xref ref-type="bibr" rid="bibr115-1753465812472940">Lee <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr157-1753465812472940">Phalitakul <italic>et al.</italic> 2011</xref>]. Increased ROS levels in the lung also augment vascular leak by stimulating endothelial permeability, thus exacerbating inflammation [<xref ref-type="bibr" rid="bibr155-1753465812472940">Pearse <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr201-1753465812472940">Usatyuk <italic>et al.</italic> 2003</xref>]. ROS also participate in hypoxia-induced pulmonary vascular leak [<xref ref-type="bibr" rid="bibr214-1753465812472940">Wojciak-Stothard <italic>et al.</italic> 2005</xref>]. This effect involves increased expression and activation of the transient receptor potential melastatin (TRPM)2 [<xref ref-type="bibr" rid="bibr58-1753465812472940">Frey <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr84-1753465812472940">Hecquet <italic>et al.</italic> 2008</xref>], as well as increased VEGF expression, triggered by ROS-induced HIF-1α activation [<xref ref-type="bibr" rid="bibr91-1753465812472940">Irwin <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr111-1753465812472940">Lee <italic>et al.</italic> 2006</xref>]. Finally, a direct role of pro-inflammatory cytokines such as IL-1β or TNF-α has been recently shown in endothelial dysfunction, involving activation of NADPH oxidase and ROS production in endothelial cells [<xref ref-type="bibr" rid="bibr7-1753465812472940">Barbieri <italic>et al.</italic> 2011</xref>]. These results therefore suggest that oxidative stress, by regulating inflammatory signalling pathways and expression of inflammatory targets in the lung, may participate in vascular inflammation in PH (<xref ref-type="fig" rid="fig4-1753465812472940">Figure 4</xref>).</p>
</sec>
</sec>
</sec>
<sec id="section27-1753465812472940">
<title>Future directions and conclusions</title>
<p>Over recent years, a large body of evidence has shown an increased oxidative stress in PH, with ROS playing multiple roles in the pathogenesis of this disease. Current PH treatments, mainly designed to target altered pulmonary arterial reactivity, manage to slow the progression of the disease but do not afford a cure. In this context, targeting ROS seems to be an interesting therapeutic approach. Indeed, ROS participate in pulmonary vascular altered reactivity, but are also involved in pulmonary vascular inflammation and remodelling, two other major PH features. Several therapeutic strategies have therefore been developed to reduce ROS levels in PH [<xref ref-type="bibr" rid="bibr56-1753465812472940">Frazziano <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr189-1753465812472940">Tabima <italic>et al.</italic> 2012</xref>].</p>
<p>A first strategy developed is to use ROS scavengers. For example, catalase and SOD mimetics decrease ROS levels and exert preventive effects in experimental PH [<xref ref-type="bibr" rid="bibr3-1753465812472940">Archer <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr38-1753465812472940">Delannoy <italic>et al.</italic> 2010</xref>]. In addition, use of recombinant human SOD [<xref ref-type="bibr" rid="bibr52-1753465812472940">Farrow <italic>et al.</italic> 2008</xref>] and gene transfer of extracellular SOD [<xref ref-type="bibr" rid="bibr98-1753465812472940">Kamezaki <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr145-1753465812472940">Nozik-Grayck <italic>et al.</italic> 2008</xref>] have shown beneficial effects in PH animal models.</p>
<p>Another strategy is the disruption of sources of ROS in the pulmonary vasculature. Use of several pharmacological inhibitors have shown beneficial effects in experimental PH, such as inhibition of uncoupled eNOS with L-NAME [<xref ref-type="bibr" rid="bibr218-1753465812472940">Wunderlich <italic>et al.</italic> 2008</xref>], or inhibition of XO with allopurinol [<xref ref-type="bibr" rid="bibr94-1753465812472940">Jankov <italic>et al.</italic> 2008</xref>]. Therapies targeting the altered mitochondrial metabolism are also investigated and constitute a promising approach, as shown by dichloroacetate, an inhibitor of mitochondrial pyruvate dehydrogenase kinase that displays curative effects in PH animal models [<xref ref-type="bibr" rid="bibr17-1753465812472940">Bonnet <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr126-1753465812472940">McMurtry <italic>et al.</italic> 2004</xref>]. Another approach consists of targeting the fatty acid oxidation pathway, through activation of the peroxisome proliferator-activated receptor (PPAR)γ [<xref ref-type="bibr" rid="bibr162-1753465812472940">Rabinovitch, 2010</xref>]. The PPARγ agonist rosiglitazone attenuates hypoxia-induced PH in the rat [<xref ref-type="bibr" rid="bibr101-1753465812472940">Kim <italic>et al.</italic> 2010</xref>], through regulation of NF-κB and HIF-1α activity [<xref ref-type="bibr" rid="bibr99-1753465812472940">Kang <italic>et al.</italic> 2011</xref>], and leading in particular to decreased Nox4 expression and decreased ROS production [<xref ref-type="bibr" rid="bibr121-1753465812472940">Lu <italic>et al.</italic> 2010</xref>]. These results therefore suggest PPARγ as a potential PH therapeutic target. However, adverse cardiovascular and cancer events detected in diabetic patients for rosiglitazone and pioglitazone, respectively, emphasize the need for caution before employing these agents in PH patients [<xref ref-type="bibr" rid="bibr69-1753465812472940">Green <italic>et al.</italic> 2011</xref>].</p>
<p>Finally, particular attention is given to NADPH oxidases. Indeed, Nox enzymes are involved in many pulmonary vascular mechanisms, and recent findings suggest their pivotal role in PH. NADPH oxidase inhibitors prevent and reverse PH in animal models [<xref ref-type="bibr" rid="bibr41-1753465812472940">Dennis <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr119-1753465812472940">Liu <italic>et al.</italic> 2006</xref>]. Further evidence comes from genetically modified mice lacking NAPDH oxidase and therefore protected from experimental PH [<xref ref-type="bibr" rid="bibr57-1753465812472940">Fresquet <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr111-1753465812472940">Lee <italic>et al.</italic> 2006</xref>]. Development of specific Nox inhibitors designed to modulate Nox isoforms in pulmonary vascular cells may therefore be of interest in PH patients [<xref ref-type="bibr" rid="bibr56-1753465812472940">Frazziano <italic>et al.</italic> 2012</xref>].</p>
<p>In conclusion, many studies have shown enhanced oxidative stress associated with PH, and evidenced an important role of ROS in various pathophysiological aspects of this disease. New therapeutic approaches in PH targeting ROS through blockade of ROS-dependent signalling pathways, or through disruption of sources of ROS in the pulmonary vasculature, targeting in particular Nox enzymes, remain therefore promising.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest in preparing this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>M.</given-names></name>
<name><surname>Kelly</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Kandhi</surname><given-names>S.</given-names></name>
<name><surname>Wolin</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Roles for Nox4 in the contractile response of bovine pulmonary arteries to hypoxia</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>298</volume>: <fpage>H1879</fpage>-<lpage>H1888</lpage>.</citation>
</ref>
<ref id="bibr2-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alderton</surname><given-names>W.</given-names></name>
<name><surname>Cooper</surname><given-names>C.</given-names></name>
<name><surname>Knowles</surname><given-names>R.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Nitric oxide synthases: structure, function and inhibition</article-title>. <source>Biochem J</source> <volume>357</volume>: <fpage>593</fpage>-<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr3-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Archer</surname><given-names>S.</given-names></name>
<name><surname>Marsboom</surname><given-names>G.</given-names></name>
<name><surname>Kim</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Toth</surname><given-names>P.</given-names></name>
<name><surname>Svensson</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target</article-title>. <source>Circulation</source> <volume>121</volume>: <fpage>2661</fpage>-<lpage>2671</lpage>.</citation>
</ref>
<ref id="bibr4-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Archer</surname><given-names>S.</given-names></name>
<name><surname>Michelakis</surname><given-names>E.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension</article-title>. <source>N Engl J Med</source> <volume>361</volume>:<fpage>1864</fpage>-<lpage>1871</lpage>.</citation>
</ref>
<ref id="bibr5-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bailey</surname><given-names>S.</given-names></name>
<name><surname>Mitra</surname><given-names>S.</given-names></name>
<name><surname>Flavahan</surname><given-names>S.</given-names></name>
<name><surname>Flavahan</surname><given-names>N.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>289</volume>: <fpage>H243</fpage>-<lpage>H250</lpage>.</citation>
</ref>
<ref id="bibr6-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Banquet</surname><given-names>S.</given-names></name>
<name><surname>Delannoy</surname><given-names>E.</given-names></name>
<name><surname>Agouni</surname><given-names>A.</given-names></name>
<name><surname>Dessy</surname><given-names>C.</given-names></name>
<name><surname>Lacomme</surname><given-names>S.</given-names></name>
<name><surname>Hubert</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Role of G(i/o)-Src kinase-PI3K/Akt pathway and caveolin-1 in beta(2)-adrenoceptor coupling to endothelial NO synthase in mouse pulmonary artery</article-title>. <source>Cell Signal</source> <volume>23</volume>: <fpage>1136</fpage>-<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr7-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbieri</surname><given-names>S.</given-names></name>
<name><surname>Zacchi</surname><given-names>E.</given-names></name>
<name><surname>Amadio</surname><given-names>P.</given-names></name>
<name><surname>Gianellini</surname><given-names>S.</given-names></name>
<name><surname>Mussoni</surname><given-names>L.</given-names></name>
<name><surname>Weksler</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Cytokines present in smokers’ serum interact with smoke components to enhance endothelial dysfunction</article-title>. <source>Cardiovasc Res</source> <volume>90</volume>: <fpage>475</fpage>-<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr8-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barchowsky</surname><given-names>A.</given-names></name>
<name><surname>Munro</surname><given-names>S.</given-names></name>
<name><surname>Morana</surname><given-names>S.</given-names></name>
<name><surname>Vincenti</surname><given-names>M.</given-names></name>
<name><surname>Treadwell</surname><given-names>M.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Oxidant-sensitive and phosphorylation-dependent activation of NF-kappa B and AP-1 in endothelial cells</article-title>. <source>Am J Physiol</source> <volume>269</volume>: <fpage>L829</fpage>-<lpage>L836</lpage>.</citation>
</ref>
<ref id="bibr9-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bayraktutan</surname><given-names>U.</given-names></name>
<name><surname>Blayney</surname><given-names>L.</given-names></name>
<name><surname>Shah</surname><given-names>A.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>20</volume>: <fpage>1903</fpage>-<lpage>1911</lpage>.</citation>
</ref>
<ref id="bibr10-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Belik</surname><given-names>J.</given-names></name>
<name><surname>Jerkic</surname><given-names>M.</given-names></name>
<name><surname>McIntyre</surname><given-names>B.</given-names></name>
<name><surname>Pan</surname><given-names>J.</given-names></name>
<name><surname>Leen</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Age-dependent endothelial nitric oxide synthase uncoupling in pulmonary arteries of endoglin heterozygous mice</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>297</volume>: <fpage>L1170</fpage>-<lpage>L1178</lpage>.</citation>
</ref>
<ref id="bibr11-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bendall</surname><given-names>J.</given-names></name>
<name><surname>Alp</surname><given-names>N.</given-names></name>
<name><surname>Warrick</surname><given-names>N.</given-names></name>
<name><surname>Cai</surname><given-names>S.</given-names></name>
<name><surname>Adlam</surname><given-names>D.</given-names></name>
<name><surname>Rockett</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression</article-title>. <source>Circ Res</source> <volume>97</volume>: <fpage>864</fpage>-<lpage>871</lpage>.</citation>
</ref>
<ref id="bibr12-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Billaud</surname><given-names>M.</given-names></name>
<name><surname>Marthan</surname><given-names>R.</given-names></name>
<name><surname>Savineau</surname><given-names>J.</given-names></name>
<name><surname>Guibert</surname><given-names>C.</given-names></name>
</person-group>(<year>2009</year>) <article-title>Vascular smooth muscle modulates endothelial control of vasoreactivity via reactive oxygen species production through myoendothelial communications</article-title>. <source>PLoS One</source> <volume>4</volume>(<issue>7</issue>): <fpage>e6432</fpage>.</citation>
</ref>
<ref id="bibr13-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Birukov</surname><given-names>K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Cyclic stretch, reactive oxygen species, and vascular remodeling</article-title>. <source>Antioxid Redox Signal</source> <volume>11</volume>: <fpage>1651</fpage>-<lpage>1667</lpage>.</citation>
</ref>
<ref id="bibr14-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Black</surname><given-names>S.</given-names></name>
<name><surname>DeVol</surname><given-names>J.</given-names></name>
<name><surname>Wedgwood</surname><given-names>S.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation</article-title>. <source>Am J Physiol Cell Physiol</source> <volume>294</volume>: <fpage>C345</fpage>-<lpage>C354</lpage>.</citation>
</ref>
<ref id="bibr15-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bokoch</surname><given-names>G.</given-names></name>
<name><surname>Knaus</surname><given-names>U.</given-names></name>
</person-group> (<year>2003</year>) <article-title>NADPH oxidases: not just for leukocytes anymore!</article-title> <source>Trends Biochem Sci</source> <volume>28</volume>: <fpage>502</fpage>-<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr16-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonnet</surname><given-names>S.</given-names></name>
<name><surname>Archer</surname><given-names>S.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension</article-title>. <source>Pharmacol Ther</source> <volume>115</volume>: <fpage>56</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr17-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonnet</surname><given-names>S.</given-names></name>
<name><surname>Michelakis</surname><given-names>E.</given-names></name>
<name><surname>Porter</surname><given-names>C.</given-names></name>
<name><surname>Andrade-Navarro</surname><given-names>M.</given-names></name>
<name><surname>Thebaud</surname><given-names>B.</given-names></name>
<name><surname>Bonnet</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension</article-title>. <source>Circulation</source> <volume>113</volume>: <fpage>2630</fpage>-<lpage>2641</lpage>.</citation>
</ref>
<ref id="bibr18-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borges</surname><given-names>F.</given-names></name>
<name><surname>Fernandes</surname><given-names>E.</given-names></name>
<name><surname>Roleira</surname><given-names>F.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Progress towards the discovery of xanthine oxidase inhibitors</article-title>. <source>Curr Med Chem</source> <volume>9</volume>: <fpage>195</fpage>-<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr19-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bowers</surname><given-names>R.</given-names></name>
<name><surname>Cool</surname><given-names>C.</given-names></name>
<name><surname>Murphy</surname><given-names>R.</given-names></name>
<name><surname>Tuder</surname><given-names>R.</given-names></name>
<name><surname>Hopken</surname><given-names>M.</given-names></name>
<name><surname>Flores</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Oxidative stress in severe pulmonary hypertension</article-title>. <source>Am J Respir Crit Care Med</source> <volume>169</volume>: <fpage>764</fpage>-<lpage>769</lpage>.</citation>
</ref>
<ref id="bibr20-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brandes</surname><given-names>R.</given-names></name>
<name><surname>Kreuzer</surname><given-names>J.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Vascular NADPH oxidases: molecular mechanisms of activation</article-title>. <source>Cardiovasc Res</source> <volume>65</volume>: <fpage>16</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr21-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brandes</surname><given-names>R.</given-names></name>
<name><surname>Weissmann</surname><given-names>N.</given-names></name>
<name><surname>Schroder</surname><given-names>K.</given-names></name>
</person-group> (<year>2010</year>) <article-title>NADPH oxidases in cardiovascular disease</article-title>. <source>Free Radic Biol Med</source> <volume>49</volume>: <fpage>687</fpage>-<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr22-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brennan</surname><given-names>L.</given-names></name>
<name><surname>Steinhorn</surname><given-names>R.</given-names></name>
<name><surname>Wedgwood</surname><given-names>S.</given-names></name>
<name><surname>Mata-Greenwood</surname><given-names>E.</given-names></name>
<name><surname>Roark</surname><given-names>E.</given-names></name>
<name><surname>Russell</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase</article-title>. <source>Circ Res</source> <volume>92</volume>: <fpage>683</fpage>-<lpage>691</lpage>.</citation>
</ref>
<ref id="bibr23-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broughton</surname><given-names>B.</given-names></name>
<name><surname>Jernigan</surname><given-names>N.</given-names></name>
<name><surname>Norton</surname><given-names>C.</given-names></name>
<name><surname>Walker</surname><given-names>B.</given-names></name>
<name><surname>Resta</surname><given-names>T.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Chronic hypoxia augments depolarization-induced Ca<sup>2+</sup> sensitization in pulmonary vascular smooth muscle through superoxide-dependent stimulation of RhoA</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>298</volume>: <fpage>L232</fpage>-<lpage>L242</lpage>.</citation>
</ref>
<ref id="bibr24-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Browning</surname><given-names>E.</given-names></name>
<name><surname>Chatterjee</surname><given-names>S.</given-names></name>
<name><surname>Fisher</surname><given-names>A.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Stop the flow: a paradigm for cell signaling mediated by reactive oxygen species in the pulmonary endothelium</article-title>. <source>Annu Rev Physiol</source> <volume>74</volume>: <fpage>403</fpage>-<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr25-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cai</surname><given-names>H.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences</article-title>. <source>Cardiovasc Res</source> <volume>68</volume>: <fpage>26</fpage>-<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr26-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cantini-Salignac</surname><given-names>C.</given-names></name>
<name><surname>Lartaud</surname><given-names>I.</given-names></name>
<name><surname>Schrijen</surname><given-names>F.</given-names></name>
<name><surname>Atkinson</surname><given-names>J.</given-names></name>
<name><surname>Chabot</surname><given-names>F.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Metalloproteinase-9 in circulating monocytes in pulmonary hypertension</article-title>. <source>Fundam Clin Pharmacol</source> <volume>20</volume>: <fpage>405</fpage>-<lpage>410</lpage>.</citation>
</ref>
<ref id="bibr27-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chakraborti</surname><given-names>S.</given-names></name>
<name><surname>Michael</surname><given-names>J.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Role of protein kinase C in oxidant-mediated activation of phospholipase A2 in rabbit pulmonary arterial smooth muscle cells</article-title>. <source>Mol Cell Biochem</source> <volume>122</volume>: <fpage>9</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr28-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chatterjee</surname><given-names>S.</given-names></name>
<name><surname>Feinstein</surname><given-names>S.</given-names></name>
<name><surname>Dodia</surname><given-names>C.</given-names></name>
<name><surname>Sorokina</surname><given-names>E.</given-names></name>
<name><surname>Lien</surname><given-names>Y.</given-names></name>
<name><surname>Nguyen</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Peroxiredoxin 6 phosphorylation and subsequent phospholipase A2 activity are required for agonist-mediated activation of NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar macrophages</article-title>. <source>J Biol Chem</source> <volume>286</volume>: <fpage>11696</fpage>-<lpage>11706</lpage>.</citation>
</ref>
<ref id="bibr29-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chelladurai</surname><given-names>P.</given-names></name>
<name><surname>Seeger</surname><given-names>W.</given-names></name>
<name><surname>Pullamsetti</surname><given-names>S.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Matrix metalloproteinases and their inhibitors in pulmonary hypertension</article-title>. <source>Eur Respir J</source> <volume>40</volume>: <fpage>766</fpage>-<lpage>782</lpage>.</citation>
</ref>
<ref id="bibr30-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Druhan</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zweier</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Superoxide induces endothelial nitric-oxide synthase protein thiyl radical formation, a novel mechanism regulating eNOS function and coupling</article-title>. <source>J Biol Chem</source> <volume>286</volume>: <fpage>29098</fpage>-<lpage>29107</lpage>.</citation>
</ref>
<ref id="bibr31-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chi</surname><given-names>A.</given-names></name>
<name><surname>Waypa</surname><given-names>G.</given-names></name>
<name><surname>Mungai</surname><given-names>P.</given-names></name>
<name><surname>Schumacker</surname><given-names>P.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Prolonged hypoxia increases ROS signaling and RhoA activation in pulmonary artery smooth muscle and endothelial cells</article-title>. <source>Antioxid Redox Signal</source> <volume>12</volume>: <fpage>603</fpage>-<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr32-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coffer</surname><given-names>P.</given-names></name>
<name><surname>Jin</surname><given-names>J.</given-names></name>
<name><surname>Woodgett</surname><given-names>J.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation</article-title>. <source>Biochem J</source> <volume>335</volume>: <fpage>1</fpage>-<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr33-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cogolludo</surname><given-names>A.</given-names></name>
<name><surname>Frazziano</surname><given-names>G.</given-names></name>
<name><surname>Cobeno</surname><given-names>L.</given-names></name>
<name><surname>Moreno</surname><given-names>L.</given-names></name>
<name><surname>Lodi</surname><given-names>F.</given-names></name>
<name><surname>Villamor</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Role of reactive oxygen species in Kv channel inhibition and vasoconstriction induced by TP receptor activation in rat pulmonary arteries</article-title>. <source>Ann N Y Acad Sci</source> <volume>1091</volume>: <fpage>41</fpage>-<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr34-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Connolly</surname><given-names>M.</given-names></name>
<name><surname>Aaronson</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Key role of the RhoA/Rho kinase system in pulmonary hypertension</article-title>. <source>Pulm Pharmacol Ther</source> <volume>24</volume>: <fpage>1</fpage>-<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr35-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cook-Mills</surname><given-names>J.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Hydrogen peroxide activation of endothelial cell-associated MMPs during VCAM-1-dependent leukocyte migration</article-title>. <source>Cell Mol Biol (Noisy-le-grand)</source> <volume>52</volume>(<issue>4</issue>): <fpage>8</fpage>-<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr36-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Courboulin</surname><given-names>A.</given-names></name>
<name><surname>Paulin</surname><given-names>R.</given-names></name>
<name><surname>Giguere</surname><given-names>N.</given-names></name>
<name><surname>Saksouk</surname><given-names>N.</given-names></name>
<name><surname>Perreault</surname><given-names>T.</given-names></name>
<name><surname>Meloche</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Role for miR-204 in human pulmonary arterial hypertension</article-title>. <source>J Exp Med</source> <volume>208</volume>: <fpage>535</fpage>-<lpage>548</lpage></citation>
</ref>
<ref id="bibr37-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crabtree</surname><given-names>M.</given-names></name>
<name><surname>Channon</surname><given-names>K.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease</article-title>. <source>Nitric Oxide</source> <volume>25</volume>(<issue>2</issue>): <fpage>81</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr38-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delannoy</surname><given-names>E.</given-names></name>
<name><surname>Courtois</surname><given-names>A.</given-names></name>
<name><surname>Freund-Michel</surname><given-names>V.</given-names></name>
<name><surname>Leblais</surname><given-names>V.</given-names></name>
<name><surname>Marthan</surname><given-names>R.</given-names></name>
<name><surname>Muller</surname><given-names>B.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Hypoxia-induced hyperreactivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, and thromboxane receptors</article-title>. <source>Cardiovasc Res</source> <volume>85</volume>: <fpage>582</fpage>-<lpage>592</lpage>.</citation>
</ref>
<ref id="bibr39-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Demarco</surname><given-names>V.</given-names></name>
<name><surname>Whaley-Connell</surname><given-names>A.</given-names></name>
<name><surname>Sowers</surname><given-names>J.</given-names></name>
<name><surname>Habibi</surname><given-names>J.</given-names></name>
<name><surname>Dellsperger</surname><given-names>K.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Contribution of oxidative stress to pulmonary arterial hypertension</article-title>. <source>World J Cardiol</source> <volume>2</volume>: <fpage>316</fpage>-<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr40-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dempsey</surname><given-names>E.</given-names></name>
<name><surname>Cool</surname><given-names>C.</given-names></name>
<name><surname>Littler</surname><given-names>C.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Lung disease and PKCs</article-title>. <source>Pharmacol Res</source> <volume>55</volume>: <fpage>545</fpage>-<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr41-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dennis</surname><given-names>K.</given-names></name>
<name><surname>Aschner</surname><given-names>J.</given-names></name>
<name><surname>Milatovic</surname><given-names>D.</given-names></name>
<name><surname>Schmidt</surname><given-names>J.</given-names></name>
<name><surname>Aschner</surname><given-names>M.</given-names></name>
<name><surname>Kaplowitz</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>NADPH oxidases and reactive oxygen species at different stages of chronic hypoxia-induced pulmonary hypertension in newborn piglets</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>297</volume>: <fpage>L596</fpage>-<lpage>L607</lpage>.</citation>
</ref>
<ref id="bibr42-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dhanasekaran</surname><given-names>A.</given-names></name>
<name><surname>Bodiga</surname><given-names>S.</given-names></name>
<name><surname>Gruenloh</surname><given-names>S.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Dunn</surname><given-names>L.</given-names></name>
<name><surname>Falck</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>20-HETE increases survival and decreases apoptosis in pulmonary arteries and pulmonary artery endothelial cells</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>296</volume>: <fpage>H777</fpage>-<lpage>H786</lpage>.</citation>
</ref>
<ref id="bibr43-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diebold</surname><given-names>I.</given-names></name>
<name><surname>Flugel</surname><given-names>D.</given-names></name>
<name><surname>Becht</surname><given-names>S.</given-names></name>
<name><surname>Belaiba</surname><given-names>R.</given-names></name>
<name><surname>Bonello</surname><given-names>S.</given-names></name>
<name><surname>Hess</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010a</year>) <article-title>The hypoxia-inducible factor-2alpha is stabilized by oxidative stress involving NOX4</article-title>. <source>Antioxid Redox Signal</source> <volume>13</volume>: <fpage>425</fpage>-<lpage>436</lpage>.</citation>
</ref>
<ref id="bibr44-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diebold</surname><given-names>I.</given-names></name>
<name><surname>Petry</surname><given-names>A.</given-names></name>
<name><surname>Djordjevic</surname><given-names>T.</given-names></name>
<name><surname>Belaiba</surname><given-names>R.</given-names></name>
<name><surname>Fineman</surname><given-names>J.</given-names></name>
<name><surname>Black</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2010b</year>) <article-title>Reciprocal regulation of Rac1 and PAK-1 by HIF-1alpha: a positive-feedback loop promoting pulmonary vascular remodeling</article-title>. <source>Antioxid Redox Signal</source> <volume>13</volume>:<fpage>399</fpage>-<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr45-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diebold</surname><given-names>I.</given-names></name>
<name><surname>Petry</surname><given-names>A.</given-names></name>
<name><surname>Hess</surname><given-names>J.</given-names></name>
<name><surname>Gorlach</surname><given-names>A.</given-names></name>
</person-group> (<year>2010c</year>) <article-title>The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1</article-title>. <source>Mol Biol Cell</source> <volume>21</volume>: <fpage>2087</fpage>-<lpage>2096</lpage>.</citation>
</ref>
<ref id="bibr46-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dietrich</surname><given-names>A.</given-names></name>
<name><surname>Gudermann</surname><given-names>T.</given-names></name>
</person-group> (<year>2011</year>) <article-title>TRP channels in the cardiopulmonary vasculature</article-title>. <source>Adv Exp Med Biol</source> <volume>704</volume>: <fpage>781</fpage>-<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr47-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Djordjevic</surname><given-names>T.</given-names></name>
<name><surname>BelAiba</surname><given-names>R.</given-names></name>
<name><surname>Bonello</surname><given-names>S.</given-names></name>
<name><surname>Pfeilschifter</surname><given-names>J.</given-names></name>
<name><surname>Hess</surname><given-names>J.</given-names></name>
<name><surname>Gorlach</surname><given-names>A.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>25</volume>: <fpage>519</fpage>-<lpage>525</lpage>.</citation>
</ref>
<ref id="bibr48-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Druhan</surname><given-names>L.</given-names></name>
<name><surname>Forbes</surname><given-names>S.</given-names></name>
<name><surname>Pope</surname><given-names>A.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Zweier</surname><given-names>J.</given-names></name>
<name><surname>Cardounel</surname><given-names>A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Regulation of eNOS-derived superoxide by endogenous methylarginines</article-title>. <source>Biochemistry</source> <volume>47</volume>: <fpage>7256</fpage>-<lpage>7263</lpage>.</citation>
</ref>
<ref id="bibr49-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dupuis</surname><given-names>J.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Endothelin-receptor antagonists in pulmonary hypertension</article-title>. <source>Lancet</source> <volume>358</volume>: <fpage>1113</fpage>-<lpage>1114</lpage>.</citation>
</ref>
<ref id="bibr50-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elmedal</surname><given-names>B.</given-names></name>
<name><surname>de Dam</surname><given-names>M.</given-names></name>
<name><surname>Mulvany</surname><given-names>M.</given-names></name>
<name><surname>Simonsen</surname><given-names>U.</given-names></name>
</person-group> (<year>2004</year>) <article-title>The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats</article-title>. <source>Br J Pharmacol</source> <volume>141</volume>: <fpage>105</fpage>-<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr51-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erusalimsky</surname><given-names>J.</given-names></name>
<name><surname>Moncada</surname><given-names>S.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Nitric oxide and mitochondrial signaling: from physiology to pathophysiology</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>27</volume>: <fpage>2524</fpage>-<lpage>2531</lpage>.</citation>
</ref>
<ref id="bibr52-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farrow</surname><given-names>K.</given-names></name>
<name><surname>Lakshminrusimha</surname><given-names>S.</given-names></name>
<name><surname>Reda</surname><given-names>W.</given-names></name>
<name><surname>Wedgwood</surname><given-names>S.</given-names></name>
<name><surname>Czech</surname><given-names>L.</given-names></name>
<name><surname>Gugino</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>295</volume>: <fpage>L979</fpage>-<lpage>L987</lpage>.</citation>
</ref>
<ref id="bibr53-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fike</surname><given-names>C.</given-names></name>
<name><surname>Aschner</surname><given-names>J.</given-names></name>
<name><surname>Slaughter</surname><given-names>J.</given-names></name>
<name><surname>Kaplowitz</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Pfister</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Pulmonary arterial responses to reactive oxygen species are altered in newborn piglets with chronic hypoxia-induced pulmonary hypertension</article-title>. <source>Pediatr Res</source> <volume>70</volume>: <fpage>136</fpage>-<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr54-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fleming</surname><given-names>I.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Molecular mechanisms underlying the activation of eNOS</article-title>. <source>Pflugers Arch</source> <volume>459</volume>: <fpage>793</fpage>-<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr55-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forstermann</surname><given-names>U.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal</article-title>. <source>Biol Chem</source> <volume>387</volume>: <fpage>1521</fpage>-<lpage>1533</lpage>.</citation>
</ref>
<ref id="bibr56-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frazziano</surname><given-names>G.</given-names></name>
<name><surname>Champion</surname><given-names>H.</given-names></name>
<name><surname>Pagano</surname><given-names>P.</given-names></name>
</person-group> (<year>2012</year>) <article-title>NADPH oxidase-derived ROS and the regulation of pulmonary vessel tone</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>302</volume>: <fpage>H2166</fpage>-<lpage>H2177</lpage>.</citation>
</ref>
<ref id="bibr57-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fresquet</surname><given-names>F.</given-names></name>
<name><surname>Pourageaud</surname><given-names>F.</given-names></name>
<name><surname>Leblais</surname><given-names>V.</given-names></name>
<name><surname>Brandes</surname><given-names>R.</given-names></name>
<name><surname>Savineau</surname><given-names>J.</given-names></name>
<name><surname>Marthan</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arteries induced by chronic hypoxia</article-title>. <source>Br J Pharmacol</source> <volume>148</volume>: <fpage>714</fpage>-<lpage>723</lpage>.</citation>
</ref>
<ref id="bibr58-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frey</surname><given-names>R.</given-names></name>
<name><surname>Ushio-Fukai</surname><given-names>M.</given-names></name>
<name><surname>Malik</surname><given-names>A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology</article-title>. <source>Antioxid Redox Signal</source> <volume>11</volume>: <fpage>791</fpage>-<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr59-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frisdal</surname><given-names>E.</given-names></name>
<name><surname>Gest</surname><given-names>V.</given-names></name>
<name><surname>Vieillard-Baron</surname><given-names>A.</given-names></name>
<name><surname>Levame</surname><given-names>M.</given-names></name>
<name><surname>Lepetit</surname><given-names>H.</given-names></name>
<name><surname>Eddahibi</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension</article-title>. <source>Eur Respir J</source> <volume>18</volume>:<fpage>838</fpage>-<lpage>845</lpage>.</citation>
</ref>
<ref id="bibr60-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frumkin</surname><given-names>L.</given-names></name>
</person-group> (<year>2012</year>) <article-title>The pharmacological treatment of pulmonary arterial hypertension</article-title>. <source>Pharmacol Rev</source> <volume>64</volume>: <fpage>583</fpage>-<lpage>620</lpage>.</citation>
</ref>
<ref id="bibr61-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>B.</given-names></name>
<name><surname>Sommer</surname><given-names>N.</given-names></name>
<name><surname>Dietrich</surname><given-names>A.</given-names></name>
<name><surname>Schermuly</surname><given-names>R.</given-names></name>
<name><surname>Ghofrani</surname><given-names>H.</given-names></name>
<name><surname>Grimminger</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction</article-title>. <source>Respir Physiol Neurobiol</source> <volume>174</volume>: <fpage>282</fpage>-<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr62-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galie</surname><given-names>N.</given-names></name>
<name><surname>Olschewski</surname><given-names>H.</given-names></name>
<name><surname>Oudiz</surname><given-names>R.</given-names></name>
<name><surname>Torres</surname><given-names>F.</given-names></name>
<name><surname>Frost</surname><given-names>A.</given-names></name>
<name><surname>Ghofrani</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2008a</year>) <article-title>Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2</article-title>. <source>Circulation</source> <volume>117</volume>: <fpage>3010</fpage>-<lpage>3019</lpage>.</citation>
</ref>
<ref id="bibr63-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galie</surname><given-names>N.</given-names></name>
<name><surname>Rubin</surname><given-names>L.</given-names></name>
<name><surname>Hoeper</surname><given-names>M.</given-names></name>
<name><surname>Jansa</surname><given-names>P.</given-names></name>
<name><surname>Al-Hiti</surname><given-names>H.</given-names></name>
<name><surname>Meyer</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2008b</year>) <article-title>Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial</article-title>. <source>Lancet</source> <volume>371</volume>: <fpage>2093</fpage>-<lpage>2100</lpage>.</citation>
</ref>
<ref id="bibr64-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galie</surname><given-names>N.</given-names></name>
<name><surname>Seeger</surname><given-names>W.</given-names></name>
<name><surname>Naeije</surname><given-names>R.</given-names></name>
<name><surname>Simonneau</surname><given-names>G.</given-names></name>
<name><surname>Rubin</surname><given-names>L.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension</article-title>. <source>J Am Coll Cardiol</source> <volume>43</volume>(<issue>12</issue> <supplement>Suppl. S</supplement>): <fpage>81S</fpage>-<lpage>88S</lpage>.</citation>
</ref>
<ref id="bibr65-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>George</surname><given-names>J.</given-names></name>
<name><surname>D’Armiento</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Transgenic expression of human matrix metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hypertension in mice</article-title>. <source>J Hypertens</source> <volume>29</volume>: <fpage>299</fpage>-<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr66-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gielis</surname><given-names>J.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Wingler</surname><given-names>K.</given-names></name>
<name><surname>Van Schil</surname><given-names>P.</given-names></name>
<name><surname>Schmidt</surname><given-names>H.</given-names></name>
<name><surname>Moens</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders</article-title>. <source>Free Radic Biol Med</source> <volume>50</volume>: <fpage>765</fpage>-<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr67-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gomberg-Maitland</surname><given-names>M.</given-names></name>
<name><surname>Olschewski</surname><given-names>H.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Prostacyclin therapies for the treatment of pulmonary arterial hypertension</article-title>. <source>Eur Respir J</source> <volume>31</volume>: <fpage>891</fpage>-<lpage>901</lpage>.</citation>
</ref>
<ref id="bibr68-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gongora</surname><given-names>M.</given-names></name>
<name><surname>Qin</surname><given-names>Z.</given-names></name>
<name><surname>Laude</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>McCann</surname><given-names>L.</given-names></name>
<name><surname>Folz</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Role of extracellular superoxide dismutase in hypertension</article-title>. <source>Hypertension</source> <volume>48</volume>: <fpage>473</fpage>-<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr69-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>D.</given-names></name>
<name><surname>Sutliff</surname><given-names>R.</given-names></name>
<name><surname>Hart</surname><given-names>C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Is peroxisome proliferator-activated receptor gamma (PPARgamma) a therapeutic target for the treatment of pulmonary hypertension?</article-title> <source>Pulm Circ</source> <volume>1</volume>: <fpage>33</fpage>-<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr70-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griendling</surname><given-names>K.</given-names></name>
<name><surname>Minieri</surname><given-names>C.</given-names></name>
<name><surname>Ollerenshaw</surname><given-names>J.</given-names></name>
<name><surname>Alexander</surname><given-names>R.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells</article-title>. <source>Circ Res</source> <volume>74</volume>: <fpage>1141</fpage>-<lpage>1148</lpage>.</citation>
</ref>
<ref id="bibr71-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griendling</surname><given-names>K.</given-names></name>
<name><surname>Sorescu</surname><given-names>D.</given-names></name>
<name><surname>Lassegue</surname><given-names>B.</given-names></name>
<name><surname>Ushio-Fukai</surname><given-names>M.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>20</volume>: <fpage>2175</fpage>-<lpage>2183</lpage>.</citation>
</ref>
<ref id="bibr72-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griffith</surname><given-names>B.</given-names></name>
<name><surname>Pendyala</surname><given-names>S.</given-names></name>
<name><surname>Hecker</surname><given-names>L.</given-names></name>
<name><surname>Lee</surname><given-names>P.</given-names></name>
<name><surname>Natarajan</surname><given-names>V.</given-names></name>
<name><surname>Thannickal</surname><given-names>V.</given-names></name>
</person-group> (<year>2009</year>) <article-title>NOX enzymes and pulmonary disease</article-title>. <source>Antioxid Redox Signal</source> <volume>11</volume>: <fpage>2505</fpage>-<lpage>2516</lpage>.</citation>
</ref>
<ref id="bibr73-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grobe</surname><given-names>A.</given-names></name>
<name><surname>Wells</surname><given-names>S.</given-names></name>
<name><surname>Benavidez</surname><given-names>E.</given-names></name>
<name><surname>Oishi</surname><given-names>P.</given-names></name>
<name><surname>Azakie</surname><given-names>A.</given-names></name>
<name><surname>Fineman</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>290</volume>: <fpage>L1069</fpage>-<lpage>L1077</lpage>.</citation>
</ref>
<ref id="bibr74-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guibert</surname><given-names>C.</given-names></name>
<name><surname>Ducret</surname><given-names>T.</given-names></name>
<name><surname>Savineau</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Expression and physiological roles of TRP channels in smooth muscle cells</article-title>. <source>Adv Exp Med Biol</source> <volume>704</volume>: <fpage>687</fpage>-<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr75-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guibert</surname><given-names>C.</given-names></name>
<name><surname>Marthan</surname><given-names>R.</given-names></name>
<name><surname>Savineau</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Modulation of ion channels in pulmonary arterial hypertension</article-title>. <source>Curr Pharm Des</source> <volume>13</volume>: <fpage>2443</fpage>-<lpage>2455</lpage>.</citation>
</ref>
<ref id="bibr76-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guzik</surname><given-names>T.</given-names></name>
<name><surname>Harrison</surname><given-names>D.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Vascular NADPH oxidases as drug targets for novel antioxidant strategies</article-title>. <source>Drug Discov Today</source> <volume>11</volume>: <fpage>524</fpage>-<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr77-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>D.</given-names></name>
<name><surname>Canali</surname><given-names>R.</given-names></name>
<name><surname>Rettori</surname><given-names>D.</given-names></name>
<name><surname>Kaplowitz</surname><given-names>N.</given-names></name>
</person-group>(<year>2003</year>) <article-title>Effect of glutathione depletion on sites and topology of superoxide and hydrogen peroxide production in mitochondria</article-title>. <source>Mol Pharmacol</source> <volume>64</volume>: <fpage>1136</fpage>-<lpage>1144</lpage>.</citation>
</ref>
<ref id="bibr78-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Moon</surname><given-names>H.</given-names></name>
<name><surname>You</surname><given-names>B.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>W.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Pyrogallol-induced endothelial cell death is related to GSH depletion rather than ROS level changes</article-title>. <source>Oncol Rep</source> <volume>23</volume>: <fpage>287</fpage>-<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr79-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanson</surname><given-names>K.</given-names></name>
<name><surname>Ziegler</surname><given-names>J.</given-names></name>
<name><surname>Rybalkin</surname><given-names>S.</given-names></name>
<name><surname>Miller</surname><given-names>J.</given-names></name>
<name><surname>Abman</surname><given-names>S.</given-names></name>
<name><surname>Clarke</surname><given-names>W.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity</article-title>. <source>Am J Physiol</source> <volume>275</volume>: <fpage>L931</fpage>-<lpage>L941</lpage>.</citation>
</ref>
<ref id="bibr80-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>R.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Structure and function of xanthine oxidoreductase: where are we now?</article-title> <source>Free Radic Biol Med</source> <volume>33</volume>: <fpage>774</fpage>-<lpage>797</lpage>.</citation>
</ref>
<ref id="bibr81-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hartney</surname><given-names>T.</given-names></name>
<name><surname>Birari</surname><given-names>R.</given-names></name>
<name><surname>Venkataraman</surname><given-names>S.</given-names></name>
<name><surname>Villegas</surname><given-names>L.</given-names></name>
<name><surname>Martinez</surname><given-names>M.</given-names></name>
<name><surname>Black</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Xanthine oxidase-derived ROS upregulate Egr-1 via ERK1/2 in PA smooth muscle cells; model to test impact of extracellular ROS in chronic hypoxia</article-title>. <source>PLoS One</source> <volume>6</volume>(<issue>11</issue>): <fpage>e27531</fpage>.</citation>
</ref>
<ref id="bibr82-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hassoun</surname><given-names>P.</given-names></name>
<name><surname>Mouthon</surname><given-names>L.</given-names></name>
<name><surname>Barbera</surname><given-names>J.</given-names></name>
<name><surname>Eddahibi</surname><given-names>S.</given-names></name>
<name><surname>Flores</surname><given-names>S.</given-names></name>
<name><surname>Grimminger</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Inflammation, growth factors, and pulmonary vascular remodeling</article-title>. <source>J Am Coll Cardiol</source> <volume>54</volume>(<supplement>1 Suppl.</supplement>): <fpage>S10</fpage>-<lpage>S19</lpage>.</citation>
</ref>
<ref id="bibr83-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haurani</surname><given-names>M.</given-names></name>
<name><surname>Pagano</surname><given-names>P.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Adventitial fibroblast reactive oxygen species as autocrine and paracrine mediators of remodeling: bellwether for vascular disease?</article-title> <source>Cardiovasc Res</source> <volume>75</volume>: <fpage>679</fpage>-<lpage>689</lpage>.</citation>
</ref>
<ref id="bibr84-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hecquet</surname><given-names>C.</given-names></name>
<name><surname>Ahmmed</surname><given-names>G.</given-names></name>
<name><surname>Vogel</surname><given-names>S.</given-names></name>
<name><surname>Malik</surname><given-names>A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Role of TRPM2 channel in mediating H<sub>2</sub>O<sub>2</sub>-induced Ca<sup>2+</sup> entry and endothelial hyperpermeability</article-title>. <source>Circ Res</source> <volume>102</volume>: <fpage>347</fpage>-<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr85-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoshikawa</surname><given-names>Y.</given-names></name>
<name><surname>Ono</surname><given-names>S.</given-names></name>
<name><surname>Suzuki</surname><given-names>S.</given-names></name>
<name><surname>Tanita</surname><given-names>T.</given-names></name>
<name><surname>Chida</surname><given-names>M.</given-names></name>
<name><surname>Song</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia</article-title>. <source>J Appl Physiol</source> <volume>90</volume>: <fpage>1299</fpage>-<lpage>1306</lpage>.</citation>
</ref>
<ref id="bibr86-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Cai</surname><given-names>C.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Effects of mitochondrial potassium channel and membrane potential on hypoxic human pulmonary artery smooth muscle cells</article-title>. <source>Am J Respir Cell Mol Biol</source> <volume>42</volume>: <fpage>661</fpage>-<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr87-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Arany</surname><given-names>Z.</given-names></name>
<name><surname>Livingston</surname><given-names>D.</given-names></name>
<name><surname>Bunn</surname><given-names>H.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit</article-title>. <source>J Biol Chem</source> <volume>271</volume>: <fpage>32253</fpage>-<lpage>32259</lpage>.</citation>
</ref>
<ref id="bibr88-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Humbert</surname><given-names>M.</given-names></name>
<name><surname>Morrell</surname><given-names>N.</given-names></name>
<name><surname>Archer</surname><given-names>S.</given-names></name>
<name><surname>Stenmark</surname><given-names>K.</given-names></name>
<name><surname>MacLean</surname><given-names>M.</given-names></name>
<name><surname>Lang</surname><given-names>I.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Cellular and molecular pathobiology of pulmonary arterial hypertension</article-title>. <source>J Am Coll Cardiol</source> <volume>43</volume>(<issue>12</issue> <supplement>Suppl. S</supplement>): <fpage>13S</fpage>-<lpage>24S</lpage>.</citation>
</ref>
<ref id="bibr89-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huot</surname><given-names>J.</given-names></name>
<name><surname>Houle</surname><given-names>F.</given-names></name>
<name><surname>Marceau</surname><given-names>F.</given-names></name>
<name><surname>Landry</surname><given-names>J.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells</article-title>. <source>Circ Res</source> <volume>80</volume>: <fpage>383</fpage>-<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr90-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huot</surname><given-names>J.</given-names></name>
<name><surname>Houle</surname><given-names>F.</given-names></name>
<name><surname>Rousseau</surname><given-names>S.</given-names></name>
<name><surname>Deschesnes</surname><given-names>R.</given-names></name>
<name><surname>Shah</surname><given-names>G.</given-names></name>
<name><surname>Landry</surname><given-names>J.</given-names></name>
</person-group> (<year>1998</year>) <article-title>SAPK2/p38-dependent F-actin reorganization regulates early membrane blebbing during stress-induced apoptosis</article-title>. <source>J Cell Biol</source> <volume>143</volume>: <fpage>1361</fpage>-<lpage>1373</lpage>.</citation>
</ref>
<ref id="bibr91-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Irwin</surname><given-names>D.</given-names></name>
<name><surname>McCord</surname><given-names>J.</given-names></name>
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>Beckly</surname><given-names>G.</given-names></name>
<name><surname>Foreman</surname><given-names>B.</given-names></name>
<name><surname>Sullivan</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>A potential role for reactive oxygen species and the HIF-1alpha-VEGF pathway in hypoxia-induced pulmonary vascular leak</article-title>. <source>Free Radic Biol Med</source> <volume>47</volume>: <fpage>55</fpage>-<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr92-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Sturrock</surname><given-names>A.</given-names></name>
<name><surname>Wu</surname><given-names>P.</given-names></name>
<name><surname>Cahill</surname><given-names>B.</given-names></name>
<name><surname>Norman</surname><given-names>K.</given-names></name>
<name><surname>Huecksteadt</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>296</volume>: <fpage>L489</fpage>-<lpage>L499</lpage>.</citation>
</ref>
<ref id="bibr93-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jagnandan</surname><given-names>D.</given-names></name>
<name><surname>Church</surname><given-names>J.</given-names></name>
<name><surname>Banfi</surname><given-names>B.</given-names></name>
<name><surname>Stuehr</surname><given-names>D.</given-names></name>
<name><surname>Marrero</surname><given-names>M.</given-names></name>
<name><surname>Fulton</surname><given-names>D.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Novel mechanism of activation of NADPH oxidase 5. calcium sensitization via phosphorylation</article-title>. <source>J Biol Chem</source> <volume>282</volume>: <fpage>6494</fpage>-<lpage>6507</lpage>.</citation>
</ref>
<ref id="bibr94-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jankov</surname><given-names>R.</given-names></name>
<name><surname>Kantores</surname><given-names>C.</given-names></name>
<name><surname>Pan</surname><given-names>J.</given-names></name>
<name><surname>Belik</surname><given-names>J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>294</volume>: <fpage>L233</fpage>-<lpage>L245</lpage>.</citation>
</ref>
<ref id="bibr95-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jarasch</surname><given-names>E.</given-names></name>
<name><surname>Grund</surname><given-names>C.</given-names></name>
<name><surname>Bruder</surname><given-names>G.</given-names></name>
<name><surname>Heid</surname><given-names>H.</given-names></name>
<name><surname>Keenan</surname><given-names>T.</given-names></name>
<name><surname>Franke</surname><given-names>W.</given-names></name>
</person-group> (<year>1981</year>) <article-title>Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium</article-title>. <source>Cell</source> <volume>25</volume>: <fpage>67</fpage>-<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr96-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jerkic</surname><given-names>M.</given-names></name>
<name><surname>Kabir</surname><given-names>M.</given-names></name>
<name><surname>Davies</surname><given-names>A.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>McIntyre</surname><given-names>B.</given-names></name>
<name><surname>Husain</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress</article-title>. <source>Cardiovasc Res</source> <volume>92</volume>: <fpage>375</fpage>-<lpage>384</lpage>.</citation>
</ref>
<ref id="bibr97-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jernigan</surname><given-names>N.</given-names></name>
<name><surname>Walker</surname><given-names>B.</given-names></name>
<name><surname>Resta</surname><given-names>T.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Reactive oxygen species mediate RhoA/Rho kinase-induced Ca<sup>2+</sup> sensitization in pulmonary vascular smooth muscle following chronic hypoxia</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>295</volume>: <fpage>L515</fpage>-<lpage>L529</lpage>.</citation>
</ref>
<ref id="bibr98-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kamezaki</surname><given-names>F.</given-names></name>
<name><surname>Tasaki</surname><given-names>H.</given-names></name>
<name><surname>Yamashita</surname><given-names>K.</given-names></name>
<name><surname>Tsutsui</surname><given-names>M.</given-names></name>
<name><surname>Koide</surname><given-names>S.</given-names></name>
<name><surname>Nakata</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats</article-title>. <source>Am J Respir Crit Care Med</source> <volume>177</volume>: <fpage>219</fpage>-<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr99-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kang</surname><given-names>B.</given-names></name>
<name><surname>Kleinhenz</surname><given-names>J.</given-names></name>
<name><surname>Murphy</surname><given-names>T.</given-names></name>
<name><surname>Hart</surname><given-names>C.</given-names></name>
</person-group>(<year>2011</year>) <article-title>The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>301</volume>: <fpage>L881</fpage>-<lpage>L891</lpage>.</citation>
</ref>
<ref id="bibr100-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khoo</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Alp</surname><given-names>N.</given-names></name>
<name><surname>Bendall</surname><given-names>J.</given-names></name>
<name><surname>Nicoli</surname><given-names>T.</given-names></name>
<name><surname>Rockett</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension</article-title>. <source>Circulation</source> <volume>111</volume>: <fpage>2126</fpage>-<lpage>2133</lpage>.</citation>
</ref>
<ref id="bibr101-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>E.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Oh</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats</article-title>. <source>Respirology</source> <volume>15</volume>: <fpage>659</fpage>-<lpage>668</lpage>.</citation>
</ref>
<ref id="bibr102-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>N.</given-names></name>
<name><surname>Rubin</surname><given-names>L.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension</article-title>. <source>J Cardiovasc Pharmacol Ther</source> <volume>7</volume>: <fpage>9</fpage>-<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr103-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Knock</surname><given-names>G.</given-names></name>
<name><surname>Snetkov</surname><given-names>V.</given-names></name>
<name><surname>Shaifta</surname><given-names>Y.</given-names></name>
<name><surname>Connolly</surname><given-names>M.</given-names></name>
<name><surname>Drndarski</surname><given-names>S.</given-names></name>
<name><surname>Noah</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Superoxide constricts rat pulmonary arteries via Rho-kinase-mediated Ca(2+) sensitization</article-title>. <source>Free Radic Biol Med</source> <volume>46</volume>: <fpage>633</fpage>-<lpage>642</lpage>.</citation>
</ref>
<ref id="bibr104-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Knock</surname><given-names>G.</given-names></name>
<name><surname>Snetkov</surname><given-names>V.</given-names></name>
<name><surname>Shaifta</surname><given-names>Y.</given-names></name>
<name><surname>Drndarski</surname><given-names>S.</given-names></name>
<name><surname>Ward</surname><given-names>J.</given-names></name>
<name><surname>Aaronson</surname><given-names>P.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Role of src-family kinases in hypoxic vasoconstriction of rat pulmonary artery</article-title>. <source>Cardiovasc Res</source> <volume>80</volume>: <fpage>453</fpage>-<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr105-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Knock</surname><given-names>G.</given-names></name>
<name><surname>Ward</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Redox regulation of protein kinases as a modulator of vascular function</article-title>. <source>Antioxid Redox Signal</source> <volume>15</volume>: <fpage>1531</fpage>-<lpage>1547</lpage>.</citation>
</ref>
<ref id="bibr106-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Konduri</surname><given-names>G.</given-names></name>
<name><surname>Bakhutashvili</surname><given-names>I.</given-names></name>
<name><surname>Eis</surname><given-names>A.</given-names></name>
<name><surname>Pritchard</surname><given-names>K.</given-names><suffix>Jr</suffix></name>
</person-group> (<year>2007</year>) <article-title>Oxidant stress from uncoupled nitric oxide synthase impairs vasodilation in fetal lambs with persistent pulmonary hypertension</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>292</volume>: <fpage>H1812</fpage>-<lpage>H1820</lpage>.</citation>
</ref>
<ref id="bibr107-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lai</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Antioxidants attenuate chronic hypoxic pulmonary hypertension</article-title>. <source>J Cardiovasc Pharmacol</source> <volume>32</volume>: <fpage>714</fpage>-<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr108-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lakshminrusimha</surname><given-names>S.</given-names></name>
<name><surname>Wiseman</surname><given-names>D.</given-names></name>
<name><surname>Black</surname><given-names>S.</given-names></name>
<name><surname>Russell</surname><given-names>J.</given-names></name>
<name><surname>Gugino</surname><given-names>S.</given-names></name>
<name><surname>Oishi</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>The role of nitric oxide synthase-derived reactive oxygen species in the altered relaxation of pulmonary arteries from lambs with increased pulmonary blood flow</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>293</volume>: <fpage>H1491</fpage>-<lpage>H1497</lpage>.</citation>
</ref>
<ref id="bibr109-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leblais</surname><given-names>V.</given-names></name>
<name><surname>Delannoy</surname><given-names>E.</given-names></name>
<name><surname>Fresquet</surname><given-names>F.</given-names></name>
<name><surname>Begueret</surname><given-names>H.</given-names></name>
<name><surname>Bellance</surname><given-names>N.</given-names></name>
<name><surname>Banquet</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>beta-adrenergic relaxation in pulmonary arteries: preservation of the endothelial nitric oxide-dependent beta2 component in pulmonary hypertension</article-title>. <source>Cardiovasc Res</source> <volume>77</volume>: <fpage>202</fpage>-<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr110-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>I.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases</article-title>. <source>Biochem Pharmacol</source> <volume>84</volume>:<fpage>581</fpage>-<lpage>590</lpage>.</citation>
</ref>
<ref id="bibr111-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<name><surname>Park</surname><given-names>C.</given-names></name>
<name><surname>Chung</surname><given-names>H.</given-names></name>
<name><surname>Rha</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression</article-title>. <source>Clin Cancer Res</source> <volume>12</volume>: <fpage>6351</fpage>-<lpage>6358</lpage>.</citation>
</ref>
<ref id="bibr112-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Esselman</surname><given-names>W.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways</article-title>. <source>Free Radic Biol Med</source> <volume>33</volume>: <fpage>1121</fpage>-<lpage>1132</lpage>.</citation>
</ref>
<ref id="bibr113-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Simon</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Fanburg</surname><given-names>B.</given-names></name>
</person-group> (<year>2001</year>) <article-title>H(2)O(2) signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>281</volume>: <fpage>L646</fpage>-<lpage>L652</lpage>.</citation>
</ref>
<ref id="bibr114-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Finlay</surname><given-names>G.</given-names></name>
<name><surname>Fanburg</surname><given-names>B.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion</article-title>. <source>Am J Physiol</source> <volume>277</volume>: <fpage>L282</fpage>-<lpage>L291</lpage>.</citation>
</ref>
<ref id="bibr115-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>W.</given-names></name>
<name><surname>Kim</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Role of NADPH oxidase in interleukin-4-induced monocyte chemoattractant protein-1 expression in vascular endothelium</article-title>. <source>Inflamm Res</source> <volume>59</volume>: <fpage>755</fpage>-<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr116-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lepetit</surname><given-names>H.</given-names></name>
<name><surname>Eddahibi</surname><given-names>S.</given-names></name>
<name><surname>Fadel</surname><given-names>E.</given-names></name>
<name><surname>Frisdal</surname><given-names>E.</given-names></name>
<name><surname>Munaut</surname><given-names>C.</given-names></name>
<name><surname>Noel</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension</article-title>. <source>Eur Respir J</source> <volume>25</volume>: <fpage>834</fpage>-<lpage>842</lpage>.</citation>
</ref>
<ref id="bibr117-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Shah</surname><given-names>A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source> <volume>287</volume>: <fpage>R1014</fpage>-<lpage>R1030</lpage>.</citation>
</ref>
<ref id="bibr118-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Tabar</surname><given-names>S.</given-names></name>
<name><surname>Malec</surname><given-names>V.</given-names></name>
<name><surname>Eul</surname><given-names>B.</given-names></name>
<name><surname>Klepetko</surname><given-names>W.</given-names></name>
<name><surname>Weissmann</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts</article-title>. <source>Antioxid Redox Signal</source> <volume>10</volume>: <fpage>1687</fpage>-<lpage>1698</lpage>.</citation>
</ref>
<ref id="bibr119-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Zelko</surname><given-names>I.</given-names></name>
<name><surname>Erbynn</surname><given-names>E.</given-names></name>
<name><surname>Sham</surname><given-names>J.</given-names></name>
<name><surname>Folz</surname><given-names>R.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox)</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>290</volume>: <fpage>L2</fpage>-<lpage>L10</lpage>.</citation>
</ref>
<ref id="bibr120-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loirand</surname><given-names>G.</given-names></name>
<name><surname>Guerin</surname><given-names>P.</given-names></name>
<name><surname>Pacaud</surname><given-names>P.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Rho kinases in cardiovascular physiology and pathophysiology</article-title>. <source>Circ Res</source> <volume>98</volume>: <fpage>322</fpage>-<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr121-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Murphy</surname><given-names>T.</given-names></name>
<name><surname>Nanes</surname><given-names>M.</given-names></name>
<name><surname>Hart</surname><given-names>C.</given-names></name>
</person-group> (<year>2010</year>) <article-title>PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>299</volume>: <fpage>L559</fpage>-<lpage>L566</lpage>.</citation>
</ref>
<ref id="bibr122-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lyle</surname><given-names>A.</given-names></name>
<name><surname>Griendling</surname><given-names>K.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Modulation of vascular smooth muscle signaling by reactive oxygen species</article-title>. <source>Physiology (Bethesda)</source> <volume>21</volume>: <fpage>269</fpage>-<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr123-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marumo</surname><given-names>T.</given-names></name>
<name><surname>Schini-Kerth</surname><given-names>V.</given-names></name>
<name><surname>Fisslthaler</surname><given-names>B.</given-names></name>
<name><surname>Busse</surname><given-names>R.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells</article-title>. <source>Circulation</source> <volume>96</volume>: <fpage>2361</fpage>-<lpage>2367</lpage>.</citation>
</ref>
<ref id="bibr124-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mata-Greenwood</surname><given-names>E.</given-names></name>
<name><surname>Grobe</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Noskina</surname><given-names>Y.</given-names></name>
<name><surname>Black</surname><given-names>S.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-beta1 and reactive oxygen species: a requirement for NAD(P)H oxidase</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>289</volume>: <fpage>L288</fpage>-<lpage>L289</lpage>.</citation>
</ref>
<ref id="bibr125-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathew</surname><given-names>R.</given-names></name>
<name><surname>Yuan</surname><given-names>N.</given-names></name>
<name><surname>Rosenfeld</surname><given-names>L.</given-names></name>
<name><surname>Gewitz</surname><given-names>M.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs</article-title>. <source>Heart Dis</source> <volume>4</volume>: <fpage>152</fpage>-<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr126-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMurtry</surname><given-names>M.</given-names></name>
<name><surname>Bonnet</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Dyck</surname><given-names>J.</given-names></name>
<name><surname>Haromy</surname><given-names>A.</given-names></name>
<name><surname>Hashimoto</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis</article-title>. <source>Circ Res</source> <volume>95</volume>:<fpage>830</fpage>-<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr127-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Medhora</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Gruenloh</surname><given-names>S.</given-names></name>
<name><surname>Harland</surname><given-names>D.</given-names></name>
<name><surname>Bodiga</surname><given-names>S.</given-names></name>
<name><surname>Zielonka</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>20-HETE increases superoxide production and activates NAPDH oxidase in pulmonary artery endothelial cells</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>294</volume>: <fpage>L902</fpage>-<lpage>L911</lpage>.</citation>
</ref>
<ref id="bibr128-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meloche</surname><given-names>S.</given-names></name>
<name><surname>Landry</surname><given-names>J.</given-names></name>
<name><surname>Huot</surname><given-names>J.</given-names></name>
<name><surname>Houle</surname><given-names>F.</given-names></name>
<name><surname>Marceau</surname><given-names>F.</given-names></name>
<name><surname>Giasson</surname><given-names>E.</given-names></name>
</person-group> (<year>2000</year>) <article-title>p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>279</volume>: <fpage>H741</fpage>-<lpage>H751</lpage>.</citation>
</ref>
<ref id="bibr129-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mermis</surname><given-names>J.</given-names></name>
<name><surname>Gu</surname><given-names>H.</given-names></name>
<name><surname>Xue</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Tawfik</surname><given-names>O.</given-names></name>
<name><surname>Buch</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Hypoxia-inducible factor-1 alpha/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling</article-title>. <source>Respir Res</source> <volume>12</volume>: <fpage>103</fpage>.</citation>
</ref>
<ref id="bibr130-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milovanova</surname><given-names>T.</given-names></name>
<name><surname>Chatterjee</surname><given-names>S.</given-names></name>
<name><surname>Manevich</surname><given-names>Y.</given-names></name>
<name><surname>Kotelnikova</surname><given-names>I.</given-names></name>
<name><surname>Debolt</surname><given-names>K.</given-names></name>
<name><surname>Madesh</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Lung endothelial cell proliferation with decreased shear stress is mediated by reactive oxygen species</article-title>. <source>Am J Physiol Cell Physiol</source> <volume>290</volume>: <fpage>C66</fpage>-<lpage>C76</lpage>.</citation>
</ref>
<ref id="bibr131-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milovanova</surname><given-names>T.</given-names></name>
<name><surname>Manevich</surname><given-names>Y.</given-names></name>
<name><surname>Haddad</surname><given-names>A.</given-names></name>
<name><surname>Chatterjee</surname><given-names>S.</given-names></name>
<name><surname>Moore</surname><given-names>J.</given-names></name>
<name><surname>Fisher</surname><given-names>A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Endothelial cell proliferation associated with abrupt reduction in shear stress is dependent on reactive oxygen species</article-title>. <source>Antioxid Redox Signal</source> <volume>6</volume>: <fpage>245</fpage>-<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr132-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mittal</surname><given-names>M.</given-names></name>
<name><surname>Roth</surname><given-names>M.</given-names></name>
<name><surname>Konig</surname><given-names>P.</given-names></name>
<name><surname>Hofmann</surname><given-names>S.</given-names></name>
<name><surname>Dony</surname><given-names>E.</given-names></name>
<name><surname>Goyal</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature</article-title>. <source>Circ Res</source> <volume>101</volume>: <fpage>258</fpage>-<lpage>267</lpage>.</citation>
</ref>
<ref id="bibr133-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montani</surname><given-names>D.</given-names></name>
<name><surname>Chaumais</surname><given-names>M.</given-names></name>
<name><surname>Savale</surname><given-names>L.</given-names></name>
<name><surname>Natali</surname><given-names>D.</given-names></name>
<name><surname>Price</surname><given-names>L.</given-names></name>
<name><surname>Jais</surname><given-names>X.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension</article-title>. <source>Adv Ther</source> <volume>26</volume>: <fpage>813</fpage>-<lpage>825</lpage>.</citation>
</ref>
<ref id="bibr134-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montani</surname><given-names>D.</given-names></name>
<name><surname>Savale</surname><given-names>L.</given-names></name>
<name><surname>Natali</surname><given-names>D.</given-names></name>
<name><surname>Jais</surname><given-names>X.</given-names></name>
<name><surname>Herve</surname><given-names>P.</given-names></name>
<name><surname>Garcia</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension</article-title>. <source>Eur Heart J</source> <volume>31</volume>: <fpage>1898</fpage>-<lpage>1907</lpage>.</citation>
</ref>
<ref id="bibr135-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Crosstalk of reactive oxygen species and NF-kappaB signaling</article-title>. <source>Cell Res</source> <volume>21</volume>: <fpage>103</fpage>-<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr136-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrell</surname><given-names>N.</given-names></name>
<name><surname>Adnot</surname><given-names>S.</given-names></name>
<name><surname>Archer</surname><given-names>S.</given-names></name>
<name><surname>Dupuis</surname><given-names>J.</given-names></name>
<name><surname>Jones</surname><given-names>P.</given-names></name>
<name><surname>MacLean</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Cellular and molecular basis of pulmonary arterial hypertension</article-title>. <source>J Am Coll Cardiol</source> <volume>54</volume>(<supplement>1 Suppl.</supplement>): <fpage>S20</fpage>-<lpage>S31</lpage>.</citation>
</ref>
<ref id="bibr137-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moudgil</surname><given-names>R.</given-names></name>
<name><surname>Michelakis</surname><given-names>E.</given-names></name>
<name><surname>Archer</surname><given-names>S.</given-names></name>
</person-group> (<year>2006</year>) <article-title>The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension</article-title>. <source>Microcirculation</source> <volume>13</volume>: <fpage>615</fpage>-<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr138-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>E.</given-names></name>
<name><surname>Steenbergen</surname><given-names>C.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury</article-title>. <source>Physiol Rev</source> <volume>88</volume>: <fpage>581</fpage>-<lpage>609</lpage>.</citation>
</ref>
<ref id="bibr139-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nandi</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>A.</given-names></name>
<name><surname>Stidwill</surname><given-names>R.</given-names></name>
<name><surname>Jacques</surname><given-names>T.</given-names></name>
<name><surname>Lam</surname><given-names>A.</given-names></name>
<name><surname>Haworth</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse</article-title>. <source>Circulation</source> <volume>111</volume>: <fpage>2086</fpage>-<lpage>2090</lpage>.</citation>
</ref>
<ref id="bibr140-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Natarajan</surname><given-names>V.</given-names></name>
<name><surname>Taher</surname><given-names>M.</given-names></name>
<name><surname>Roehm</surname><given-names>B.</given-names></name>
<name><surname>Parinandi</surname><given-names>N.</given-names></name>
<name><surname>Schmid</surname><given-names>H.</given-names></name>
<name><surname>Kiss</surname><given-names>Z.</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Activation of endothelial cell phospholipase D by hydrogen peroxide and fatty acid hydroperoxide</article-title>. <source>J Biol Chem</source> <volume>268</volume>: <fpage>930</fpage>-<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr141-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nijmeh</surname><given-names>J.</given-names></name>
<name><surname>Moldobaeva</surname><given-names>A.</given-names></name>
<name><surname>Wagner</surname><given-names>E.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Role of ROS in ischemia-induced lung angiogenesis</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>299</volume>: <fpage>L535</fpage>-<lpage>L541</lpage>.</citation>
</ref>
<ref id="bibr142-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nisbet</surname><given-names>R.</given-names></name>
<name><surname>Graves</surname><given-names>A.</given-names></name>
<name><surname>Kleinhenz</surname><given-names>D.</given-names></name>
<name><surname>Rupnow</surname><given-names>H.</given-names></name>
<name><surname>Reed</surname><given-names>A.</given-names></name>
<name><surname>Fan</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice</article-title>. <source>Am J Respir Cell Mol Biol</source> <volume>40</volume>: <fpage>601</fpage>-<lpage>609</lpage>.</citation>
</ref>
<ref id="bibr143-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nishino</surname><given-names>T.</given-names></name>
<name><surname>Okamoto</surname><given-names>K.</given-names></name>
<name><surname>Eger</surname><given-names>B.</given-names></name>
<name><surname>Pai</surname><given-names>E.</given-names></name>
<name><surname>Nishino</surname><given-names>T.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase</article-title>. <source>FEBS J</source> <volume>275</volume>: <fpage>3278</fpage>-<lpage>3289</lpage>.</citation>
</ref>
<ref id="bibr144-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noguchi</surname><given-names>K.</given-names></name>
<name><surname>Hamadate</surname><given-names>N.</given-names></name>
<name><surname>Matsuzaki</surname><given-names>T.</given-names></name>
<name><surname>Sakanashi</surname><given-names>M.</given-names></name>
<name><surname>Nakasone</surname><given-names>J.</given-names></name>
<name><surname>Uchida</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Increasing dihydrobiopterin causes dysfunction of endothelial nitric oxide synthase in rats in vivo</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>301</volume>: <fpage>H721</fpage>-<lpage>H729</lpage>.</citation>
</ref>
<ref id="bibr145-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>Suliman</surname><given-names>H.</given-names></name>
<name><surname>Majka</surname><given-names>S.</given-names></name>
<name><surname>Albietz</surname><given-names>J.</given-names></name>
<name><surname>Van Rheen</surname><given-names>Z.</given-names></name>
<name><surname>Roush</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Lung EC-SOD overexpression attenuates hypoxic induction of Egr-1 and chronic hypoxic pulmonary vascular remodeling</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>295</volume>: <fpage>L422</fpage>-<lpage>L430</lpage>.</citation>
</ref>
<ref id="bibr146-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Callaghan</surname><given-names>D.</given-names></name>
<name><surname>Savale</surname><given-names>L.</given-names></name>
<name><surname>Montani</surname><given-names>D.</given-names></name>
<name><surname>Jais</surname><given-names>X.</given-names></name>
<name><surname>Sitbon</surname><given-names>O.</given-names></name>
<name><surname>Simonneau</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Treatment of pulmonary arterial hypertension with targeted therapies</article-title>. <source>Nat Rev Cardiol</source> <volume>8</volume>: <fpage>526</fpage>-<lpage>538</lpage>.</citation>
</ref>
<ref id="bibr147-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oka</surname><given-names>M.</given-names></name>
<name><surname>Fagan</surname><given-names>K.</given-names></name>
<name><surname>Jones</surname><given-names>P.</given-names></name>
<name><surname>McMurtry</surname><given-names>I.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension</article-title>. <source>Br J Pharmacol</source> <volume>155</volume>: <fpage>444</fpage>-<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr148-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paravicini</surname><given-names>T.</given-names></name>
<name><surname>Touyz</surname><given-names>R.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Redox signaling in hypertension</article-title>. <source>Cardiovasc Res</source> <volume>71</volume>: <fpage>247</fpage>-<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr149-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parinandi</surname><given-names>N.</given-names></name>
<name><surname>Kleinberg</surname><given-names>M.</given-names></name>
<name><surname>Usatyuk</surname><given-names>P.</given-names></name>
<name><surname>Cummings</surname><given-names>R.</given-names></name>
<name><surname>Pennathur</surname><given-names>A.</given-names></name>
<name><surname>Cardounel</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>284</volume>: <fpage>L26</fpage>-<lpage>L38</lpage>.</citation>
</ref>
<ref id="bibr150-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Impact of oxidative stress on lung diseases</article-title>. <source>Respirology</source> <volume>14</volume>:<fpage>27</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr151-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Partridge</surname><given-names>C.</given-names></name>
<name><surname>Blumenstock</surname><given-names>F.</given-names></name>
<name><surname>Malik</surname><given-names>A.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Pulmonary microvascular endothelial cells constitutively release xanthine oxidase</article-title>. <source>Arch Biochem Biophys</source> <volume>294</volume>: <fpage>184</fpage>-<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr152-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patil</surname><given-names>S.</given-names></name>
<name><surname>Bunderson</surname><given-names>M.</given-names></name>
<name><surname>Wilham</surname><given-names>J.</given-names></name>
<name><surname>Black</surname><given-names>S.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Important role for Rac1 in regulating reactive oxygen species generation and pulmonary arterial smooth muscle cell growth</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>287</volume>: <fpage>L1314</fpage>-<lpage>L1322</lpage>.</citation>
</ref>
<ref id="bibr153-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paulin</surname><given-names>R.</given-names></name>
<name><surname>Meloche</surname><given-names>J.</given-names></name>
<name><surname>Jacob</surname><given-names>M.</given-names></name>
<name><surname>Bisserier</surname><given-names>M.</given-names></name>
<name><surname>Courboulin</surname><given-names>A.</given-names></name>
<name><surname>Bonnet</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>301</volume>: <fpage>H1798</fpage>-<lpage>H1809</lpage>.</citation>
</ref>
<ref id="bibr154-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pauvert</surname><given-names>O.</given-names></name>
<name><surname>Lugnier</surname><given-names>C.</given-names></name>
<name><surname>Keravis</surname><given-names>T.</given-names></name>
<name><surname>Marthan</surname><given-names>R.</given-names></name>
<name><surname>Rousseau</surname><given-names>E.</given-names></name>
<name><surname>Savineau</surname><given-names>J.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery</article-title>. <source>Br J Pharmacol</source> <volume>139</volume>: <fpage>513</fpage>-<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr155-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pearse</surname><given-names>D.</given-names></name>
<name><surname>Shimoda</surname><given-names>L.</given-names></name>
<name><surname>Verin</surname><given-names>A.</given-names></name>
<name><surname>Bogatcheva</surname><given-names>N.</given-names></name>
<name><surname>Moon</surname><given-names>C.</given-names></name>
<name><surname>Ronnett</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Effect of cGMP on lung microvascular endothelial barrier dysfunction following hydrogen peroxide</article-title>. <source>Endothelium</source> <volume>10</volume>: <fpage>309</fpage>-<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr156-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perez-Vizcaino</surname><given-names>F.</given-names></name>
<name><surname>Cogolludo</surname><given-names>A.</given-names></name>
<name><surname>Moreno</surname><given-names>L.</given-names></name>
</person-group>(<year>2010</year>) <article-title>Reactive oxygen species signaling in pulmonary vascular smooth muscle</article-title>. <source>Respir Physiol Neurobiol</source> <volume>174</volume>: <fpage>212</fpage>-<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr157-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Phalitakul</surname><given-names>S.</given-names></name>
<name><surname>Okada</surname><given-names>M.</given-names></name>
<name><surname>Hara</surname><given-names>Y.</given-names></name>
<name><surname>Yamawaki</surname><given-names>H.</given-names></name>
</person-group>(<year>2011</year>) <article-title>Vaspin prevents TNF-alpha-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kappaB and PKCtheta activation in cultured rat vascular smooth muscle cells</article-title>. <source>Pharmacol Res</source> <volume>64</volume>: <fpage>493</fpage>-<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr158-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pourmahram</surname><given-names>G.</given-names></name>
<name><surname>Snetkov</surname><given-names>V.</given-names></name>
<name><surname>Shaifta</surname><given-names>Y.</given-names></name>
<name><surname>Drndarski</surname><given-names>S.</given-names></name>
<name><surname>Knock</surname><given-names>G.</given-names></name>
<name><surname>Aaronson</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Constriction of pulmonary artery by peroxide: role of Ca<sup>2+</sup> release and PKC</article-title>. <source>Free Radic Biol Med</source> <volume>45</volume>: <fpage>1468</fpage>-<lpage>1476</lpage>.</citation>
</ref>
<ref id="bibr159-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Price</surname><given-names>L.</given-names></name>
<name><surname>Wort</surname><given-names>S.</given-names></name>
<name><surname>Perros</surname><given-names>F.</given-names></name>
<name><surname>Dorfmuller</surname><given-names>P.</given-names></name>
<name><surname>Huertas</surname><given-names>A.</given-names></name>
<name><surname>Montani</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Inflammation in pulmonary arterial hypertension</article-title>. <source>Chest</source> <volume>141</volume>: <fpage>210</fpage>-<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr160-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qipshidze</surname><given-names>N.</given-names></name>
<name><surname>Tyagi</surname><given-names>N.</given-names></name>
<name><surname>Metreveli</surname><given-names>N.</given-names></name>
<name><surname>Lominadze</surname><given-names>D.</given-names></name>
<name><surname>Tyagi</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Autophagy mechanism of right ventricular remodeling in murine model of pulmonary artery constriction</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>302</volume>: <fpage>H688</fpage>-<lpage>H696</lpage>.</citation>
</ref>
<ref id="bibr161-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quinn</surname><given-names>M.</given-names></name>
<name><surname>Gauss</surname><given-names>K.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases</article-title>. <source>J Leukoc Biol</source> <volume>76</volume>: <fpage>760</fpage>-<lpage>781</lpage>.</citation>
</ref>
<ref id="bibr162-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rabinovitch</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>PPARgamma and the pathobiology of pulmonary arterial hypertension</article-title>. <source>Adv Exp Med Biol</source> <volume>661</volume>: <fpage>447</fpage>-<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr163-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rafikov</surname><given-names>R.</given-names></name>
<name><surname>Fonseca</surname><given-names>F.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Pardo</surname><given-names>D.</given-names></name>
<name><surname>Darragh</surname><given-names>C.</given-names></name>
<name><surname>Elms</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity</article-title>. <source>J Endocrinol</source> <volume>210</volume>: <fpage>271</fpage>-<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr164-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>I.</given-names></name>
<name><surname>MacNee</surname><given-names>W.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Oxidative stress and regulation of glutathione in lung inflammation</article-title>. <source>Eur Respir J</source> <volume>16</volume>: <fpage>534</fpage>-<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr165-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rathore</surname><given-names>R.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Ginnan</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Mitochondrial ROS-PKCepsilon signaling axis is uniquely involved in hypoxic increase in [Ca<sup>2+</sup>]i in pulmonary artery smooth muscle cells</article-title>. <source>Biochem Biophys Res Commun</source> <volume>351</volume>: <fpage>784</fpage>-<lpage>790</lpage>.</citation>
</ref>
<ref id="bibr166-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rathore</surname><given-names>R.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Niu</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Korde</surname><given-names>A.</given-names></name>
<name><surname>Ho</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca<sup>2+</sup>]i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells</article-title>. <source>Free Radic Biol Med</source> <volume>45</volume>: <fpage>1223</fpage>-<lpage>1231</lpage>.</citation>
</ref>
<ref id="bibr167-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Redout</surname><given-names>E.</given-names></name>
<name><surname>van der Toorn</surname><given-names>A.</given-names></name>
<name><surname>Zuidwijk</surname><given-names>M.</given-names></name>
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Kolk</surname><given-names>C.</given-names></name>
<name><surname>van Echteld</surname><given-names>C.</given-names></name>
<name><surname>Musters</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>298</volume>: <fpage>H1038</fpage>-<lpage>H1047</lpage>.</citation>
</ref>
<ref id="bibr168-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Redout</surname><given-names>E.</given-names></name>
<name><surname>Wagner</surname><given-names>M.</given-names></name>
<name><surname>Zuidwijk</surname><given-names>M.</given-names></name>
<name><surname>Boer</surname><given-names>C.</given-names></name>
<name><surname>Musters</surname><given-names>R.</given-names></name>
<name><surname>van Hardeveld</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species</article-title>. <source>Cardiovasc Res</source> <volume>75</volume>: <fpage>770</fpage>-<lpage>781</lpage>.</citation>
</ref>
<ref id="bibr169-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Remacle</surname><given-names>J.</given-names></name>
<name><surname>Raes</surname><given-names>M.</given-names></name>
<name><surname>Toussaint</surname><given-names>O.</given-names></name>
<name><surname>Renard</surname><given-names>P.</given-names></name>
<name><surname>Rao</surname><given-names>G.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Low levels of reactive oxygen species as modulators of cell function</article-title>. <source>Mutat Res</source> <volume>316</volume>: <fpage>103</fpage>-<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr170-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Resta</surname><given-names>T.</given-names></name>
<name><surname>Broughton</surname><given-names>B.</given-names></name>
<name><surname>Jernigan</surname><given-names>N.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Reactive oxygen species and RhoA signaling in vascular smooth muscle: role in chronic hypoxia-induced pulmonary hypertension</article-title>. <source>Adv Exp Med Biol</source> <volume>661</volume>: <fpage>355</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr171-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reyland</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Protein kinase C isoforms: Multi-functional regulators of cell life and death</article-title>. <source>Front Biosci</source> <volume>14</volume>: <fpage>2386</fpage>-<lpage>2399</lpage>.</citation>
</ref>
<ref id="bibr172-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rhodes</surname><given-names>C.</given-names></name>
<name><surname>Davidson</surname><given-names>A.</given-names></name>
<name><surname>Gibbs</surname><given-names>J.</given-names></name>
<name><surname>Wharton</surname><given-names>J.</given-names></name>
<name><surname>Wilkins</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Therapeutic targets in pulmonary arterial hypertension</article-title>. <source>Pharmacol Ther</source> <volume>121</volume>: <fpage>69</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr173-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubbo</surname><given-names>H.</given-names></name>
<name><surname>Trostchansky</surname><given-names>A.</given-names></name>
<name><surname>O’Donnell</surname><given-names>V.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Peroxynitrite-mediated lipid oxidation and nitration: mechanisms and consequences</article-title>. <source>Arch Biochem Biophys</source> <volume>484</volume>: <fpage>167</fpage>-<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr174-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubin</surname><given-names>L.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Calcium channel blockers in primary pulmonary hypertension</article-title>. <source>Chest</source> <volume>88</volume>(<supplement>4 Suppl.</supplement>): <fpage>257S</fpage>-<lpage>260S</lpage>.</citation>
</ref>
<ref id="bibr175-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubin</surname><given-names>L.</given-names></name>
<name><surname>Badesch</surname><given-names>D.</given-names></name>
<name><surname>Barst</surname><given-names>R.</given-names></name>
<name><surname>Galie</surname><given-names>N.</given-names></name>
<name><surname>Black</surname><given-names>C.</given-names></name>
<name><surname>Keogh</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Bosentan therapy for pulmonary arterial hypertension</article-title>. <source>N Engl J Med</source> <volume>346</volume>: <fpage>896</fpage>-<lpage>903</lpage>.</citation>
</ref>
<ref id="bibr176-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schermuly</surname><given-names>R.</given-names></name>
<name><surname>Ghofrani</surname><given-names>H.</given-names></name>
<name><surname>Wilkins</surname><given-names>M.</given-names></name>
<name><surname>Grimminger</surname><given-names>F.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Mechanisms of disease: pulmonary arterial hypertension</article-title>. <source>Nat Rev Cardiol</source> <volume>8</volume>: <fpage>443</fpage>-<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr177-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sedeek</surname><given-names>M.</given-names></name>
<name><surname>Hebert</surname><given-names>R.</given-names></name>
<name><surname>Kennedy</surname><given-names>C.</given-names></name>
<name><surname>Burns</surname><given-names>K.</given-names></name>
<name><surname>Touyz</surname><given-names>R.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Molecular mechanisms of hypertension: role of Nox family NADPH oxidases</article-title>. <source>Curr Opin Nephrol Hypertens</source> <volume>18</volume>: <fpage>122</fpage>-<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr178-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimoda</surname><given-names>L.</given-names></name>
<name><surname>Undem</surname><given-names>C.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Interactions between calcium and reactive oxygen species in pulmonary arterial smooth muscle responses to hypoxia</article-title>. <source>Respir Physiol Neurobiol</source> <volume>174</volume>: <fpage>221</fpage>-<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr179-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simon</surname><given-names>A.</given-names></name>
<name><surname>Rai</surname><given-names>U.</given-names></name>
<name><surname>Fanburg</surname><given-names>B.</given-names></name>
<name><surname>Cochran</surname><given-names>B.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Activation of the JAK-STAT pathway by reactive oxygen species</article-title>. <source>Am J Physiol</source> <volume>275</volume>: <fpage>C1640</fpage>-<lpage>C1652</lpage>.</citation>
</ref>
<ref id="bibr180-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simonneau</surname><given-names>G.</given-names></name>
<name><surname>Robbins</surname><given-names>I.</given-names></name>
<name><surname>Beghetti</surname><given-names>M.</given-names></name>
<name><surname>Channick</surname><given-names>R.</given-names></name>
<name><surname>Delcroix</surname><given-names>M.</given-names></name>
<name><surname>Denton</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Updated clinical classification of pulmonary hypertension</article-title>. <source>J Am Coll Cardiol</source> <volume>54</volume>(<supplement>1 Suppl.</supplement>): <fpage>S43</fpage>-<lpage>S54</lpage>.</citation>
</ref>
<ref id="bibr181-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sitbon</surname><given-names>O.</given-names></name>
<name><surname>Humbert</surname><given-names>M.</given-names></name>
<name><surname>Nunes</surname><given-names>H.</given-names></name>
<name><surname>Parent</surname><given-names>F.</given-names></name>
<name><surname>Garcia</surname><given-names>G.</given-names></name>
<name><surname>Herve</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival</article-title>. <source>J Am Coll Cardiol</source> <volume>40</volume>: <fpage>780</fpage>-<lpage>788</lpage>.</citation>
</ref>
<ref id="bibr182-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>M.</given-names></name>
<name><surname>Makino</surname><given-names>A.</given-names></name>
<name><surname>Yuan</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Role of reactive oxygen species and redox in regulating the function of transient receptor potential channels</article-title>. <source>Antioxid Redox Signal</source> <volume>15</volume>: <fpage>1549</fpage>-<lpage>1565</lpage>.</citation>
</ref>
<ref id="bibr183-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spiekermann</surname><given-names>S.</given-names></name>
<name><surname>Schenk</surname><given-names>K.</given-names></name>
<name><surname>Hoeper</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension</article-title>. <source>Eur Respir J</source> <volume>34</volume>: <fpage>276</fpage>.</citation>
</ref>
<ref id="bibr184-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stenmark</surname><given-names>K.</given-names></name>
<name><surname>Frid</surname><given-names>M.</given-names></name>
<name><surname>Yeager</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Riddle</surname><given-names>S.</given-names></name>
<name><surname>McKinsey</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change</article-title>. <source>Pulm Circ</source> <volume>2</volume>: <fpage>3</fpage>-<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr185-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stowe</surname><given-names>D.</given-names></name>
<name><surname>Camara</surname><given-names>A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial and cell function</article-title>. <source>Antioxid Redox Signal</source> <volume>11</volume>: <fpage>1373</fpage>-<lpage>1414</lpage>.</citation>
</ref>
<ref id="bibr186-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sturrock</surname><given-names>A.</given-names></name>
<name><surname>Cahill</surname><given-names>B.</given-names></name>
<name><surname>Norman</surname><given-names>K.</given-names></name>
<name><surname>Huecksteadt</surname><given-names>T.</given-names></name>
<name><surname>Hill</surname><given-names>K.</given-names></name>
<name><surname>Sanders</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>290</volume>: <fpage>L661</fpage>-<lpage>L673</lpage>.</citation>
</ref>
<ref id="bibr187-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sud</surname><given-names>N.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Wiseman</surname><given-names>D.</given-names></name>
<name><surname>Harmon</surname><given-names>C.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Venema</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Nitric oxide and superoxide generation from endothelial NOS: modulation by HSP90</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>293</volume>: <fpage>L1444</fpage>-<lpage>L1453</lpage>.</citation>
</ref>
<ref id="bibr188-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sundaresan</surname><given-names>M.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
<name><surname>Ferrans</surname><given-names>V.</given-names></name>
<name><surname>Irani</surname><given-names>K.</given-names></name>
<name><surname>Finkel</surname><given-names>T.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Requirement for generation of H<sub>2</sub>O<sub>2</sub> for platelet-derived growth factor signal transduction</article-title>. <source>Science</source> <volume>270</volume>: <fpage>296</fpage>-<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr189-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tabima</surname><given-names>D.</given-names></name>
<name><surname>Frizzell</surname><given-names>S.</given-names></name>
<name><surname>Gladwin</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Reactive oxygen and nitrogen species in pulmonary hypertension</article-title>. <source>Free Radic Biol Med</source> <volume>52</volume>: <fpage>1970</fpage>-<lpage>1986</lpage>.</citation>
</ref>
<ref id="bibr190-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tajima</surname><given-names>M.</given-names></name>
<name><surname>Kurashima</surname><given-names>Y.</given-names></name>
<name><surname>Sugiyama</surname><given-names>K.</given-names></name>
<name><surname>Ogura</surname><given-names>T.</given-names></name>
<name><surname>Sakagami</surname><given-names>H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The redox state of glutathione regulates the hypoxic induction of HIF-1</article-title>. <source>Eur J Pharmacol</source> <volume>606</volume>: <fpage>45</fpage>-<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr191-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>ten Freyhaus</surname><given-names>H.</given-names></name>
<name><surname>Dagnell</surname><given-names>M.</given-names></name>
<name><surname>Leuchs</surname><given-names>M.</given-names></name>
<name><surname>Vantler</surname><given-names>M.</given-names></name>
<name><surname>Berghausen</surname><given-names>E.</given-names></name>
<name><surname>Caglayan</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases</article-title>. <source>Am J Respir Crit Care Med</source> <volume>183</volume>: <fpage>1092</fpage>-<lpage>1102</lpage>.</citation>
</ref>
<ref id="bibr192-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Terada</surname><given-names>L.</given-names></name>
<name><surname>Guidot</surname><given-names>D.</given-names></name>
<name><surname>Leff</surname><given-names>J.</given-names></name>
<name><surname>Willingham</surname><given-names>I.</given-names></name>
<name><surname>Hanley</surname><given-names>M.</given-names></name>
<name><surname>Piermattei</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>89</volume>: <fpage>3362</fpage>-<lpage>3366</lpage>.</citation>
</ref>
<ref id="bibr193-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Pharmacological targets for pulmonary vascular disease: vasodilation versus anti-remodelling</article-title>. <source>Adv Exp Med Biol</source> <volume>661</volume>: <fpage>475</fpage>-<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr194-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tonelli</surname><given-names>A.</given-names></name>
<name><surname>Alnuaimat</surname><given-names>H.</given-names></name>
<name><surname>Mubarak</surname><given-names>K.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension</article-title>. <source>Respir Med</source> <volume>104</volume>: <fpage>481</fpage>-<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr195-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tonks</surname><given-names>N.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Redox redux: revisiting PTPs and the control of cell signaling</article-title>. <source>Cell</source> <volume>121</volume>: <fpage>667</fpage>-<lpage>670</lpage>.</citation>
</ref>
<ref id="bibr196-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toporsian</surname><given-names>M.</given-names></name>
<name><surname>Jerkic</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Kabir</surname><given-names>M.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>McIntyre</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>30</volume>: <fpage>509</fpage>-<lpage>517</lpage>.</citation>
</ref>
<ref id="bibr197-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Torrecillas</surname><given-names>G.</given-names></name>
<name><surname>Boyano-Adanez</surname><given-names>M.</given-names></name>
<name><surname>Medina</surname><given-names>J.</given-names></name>
<name><surname>Parra</surname><given-names>T.</given-names></name>
<name><surname>Griera</surname><given-names>M.</given-names></name>
<name><surname>Lopez-Ongil</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>The role of hydrogen peroxide in the contractile response to angiotensin II</article-title>. <source>Mol Pharmacol</source> <volume>59</volume>: <fpage>104</fpage>-<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr198-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Touyz</surname><given-names>R.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?</article-title> <source>Hypertension</source> <volume>44</volume>: <fpage>248</fpage>-<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr199-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Touyz</surname><given-names>R.</given-names></name>
<name><surname>Briones</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Reactive oxygen species and vascular biology: implications in human hypertension</article-title>. <source>Hypertens Res</source> <volume>34</volume>: <fpage>5</fpage>-<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr200-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Umar</surname><given-names>S.</given-names></name>
<name><surname>Hessel</surname><given-names>M.</given-names></name>
<name><surname>Steendijk</surname><given-names>P.</given-names></name>
<name><surname>Bax</surname><given-names>W.</given-names></name>
<name><surname>Schutte</surname><given-names>C.</given-names></name>
<name><surname>Schalij</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension</article-title>. <source>Pathol Res Pract</source> <volume>203</volume>: <fpage>863</fpage>-<lpage>872</lpage>.</citation>
</ref>
<ref id="bibr201-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Usatyuk</surname><given-names>P.</given-names></name>
<name><surname>Vepa</surname><given-names>S.</given-names></name>
<name><surname>Watkins</surname><given-names>T.</given-names></name>
<name><surname>He</surname><given-names>D.</given-names></name>
<name><surname>Parinandi</surname><given-names>N.</given-names></name>
<name><surname>Natarajan</surname><given-names>V.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Redox regulation of reactive oxygen species-induced p38 MAP kinase activation and barrier dysfunction in lung microvascular endothelial cells</article-title>. <source>Antioxid Redox Signal</source> <volume>5</volume>: <fpage>723</fpage>-<lpage>730</lpage>.</citation>
</ref>
<ref id="bibr202-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ushio-Fukai</surname><given-names>M.</given-names></name>
<name><surname>Alexander</surname><given-names>R.</given-names></name>
<name><surname>Akers</surname><given-names>M.</given-names></name>
<name><surname>Griendling</surname><given-names>K.</given-names></name>
</person-group> (<year>1998</year>) <article-title>p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy</article-title>. <source>J Biol Chem</source> <volume>273</volume>: <fpage>15022</fpage>-<lpage>15029</lpage>.</citation>
</ref>
<ref id="bibr203-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ushio-Fukai</surname><given-names>M.</given-names></name>
<name><surname>Alexander</surname><given-names>R.</given-names></name>
<name><surname>Akers</surname><given-names>M.</given-names></name>
<name><surname>Yin</surname><given-names>Q.</given-names></name>
<name><surname>Fujio</surname><given-names>Y.</given-names></name>
<name><surname>Walsh</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells</article-title>. <source>J Biol Chem</source> <volume>274</volume>: <fpage>22699</fpage>-<lpage>22704</lpage>.</citation>
</ref>
<ref id="bibr204-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ushio-Fukai</surname><given-names>M.</given-names></name>
<name><surname>Griendling</surname><given-names>K.</given-names></name>
<name><surname>Becker</surname><given-names>P.</given-names></name>
<name><surname>Hilenski</surname><given-names>L.</given-names></name>
<name><surname>Halleran</surname><given-names>S.</given-names></name>
<name><surname>Alexander</surname><given-names>R.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>21</volume>: <fpage>489</fpage>-<lpage>495</lpage>.</citation>
</ref>
<ref id="bibr205-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Victor</surname><given-names>V.</given-names></name>
<name><surname>Rocha</surname><given-names>M.</given-names></name>
<name><surname>Sola</surname><given-names>E.</given-names></name>
<name><surname>Banuls</surname><given-names>C.</given-names></name>
<name><surname>Garcia-Malpartida</surname><given-names>K.</given-names></name>
<name><surname>Hernandez-Mijares</surname><given-names>A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Oxidative stress, endothelial dysfunction and atherosclerosis</article-title>. <source>Curr Pharm Des</source> <volume>15</volume>: <fpage>2988</fpage>-<lpage>3002</lpage>.</citation>
</ref>
<ref id="bibr206-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viedt</surname><given-names>C.</given-names></name>
<name><surname>Soto</surname><given-names>U.</given-names></name>
<name><surname>Krieger-Brauer</surname><given-names>H.</given-names></name>
<name><surname>Fei</surname><given-names>J.</given-names></name>
<name><surname>Elsing</surname><given-names>C.</given-names></name>
<name><surname>Kubler</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>20</volume>: <fpage>940</fpage>-<lpage>948</lpage>.</citation>
</ref>
<ref id="bibr207-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Voelkel</surname><given-names>N.</given-names></name>
<name><surname>Gomez-Arroyo</surname><given-names>J.</given-names></name>
<name><surname>Abbate</surname><given-names>A.</given-names></name>
<name><surname>Bogaard</surname><given-names>H.</given-names></name>
<name><surname>Nicolls</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Pathobiology of pulmonary arterial hypertension and right ventricular failure</article-title>. <source>Eur Respir J</source> <year>2012</year>; in press.</citation>
</ref>
<ref id="bibr208-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waypa</surname><given-names>G.</given-names></name>
<name><surname>Marks</surname><given-names>J.</given-names></name>
<name><surname>Guzy</surname><given-names>R.</given-names></name>
<name><surname>Mungai</surname><given-names>P.</given-names></name>
<name><surname>Schriewer</surname><given-names>J.</given-names></name>
<name><surname>Dokic</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells</article-title>. <source>Circ Res</source> <volume>106</volume>: <fpage>526</fpage>-<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr209-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waypa</surname><given-names>G.</given-names></name>
<name><surname>Marks</surname><given-names>J.</given-names></name>
<name><surname>Mack</surname><given-names>M.</given-names></name>
<name><surname>Boriboun</surname><given-names>C.</given-names></name>
<name><surname>Mungai</surname><given-names>P.</given-names></name>
<name><surname>Schumacker</surname><given-names>P.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes</article-title>. <source>Circ Res</source> <volume>91</volume>: <fpage>719</fpage>-<lpage>726</lpage>.</citation>
</ref>
<ref id="bibr210-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wedgwood</surname><given-names>S.</given-names></name>
<name><surname>Black</surname><given-names>S.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension</article-title>. <source>Antioxid Redox Signal</source> <volume>5</volume>: <fpage>759</fpage>-<lpage>769</lpage>.</citation>
</ref>
<ref id="bibr211-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wedgwood</surname><given-names>S.</given-names></name>
<name><surname>Black</surname><given-names>S.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Combined superoxide dismutase/catalase mimetics alter fetal pulmonary arterial smooth muscle cell growth</article-title>. <source>Antioxid Redox Signal</source> <volume>6</volume>: <fpage>191</fpage>-<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr212-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wedgwood</surname><given-names>S.</given-names></name>
<name><surname>Dettman</surname><given-names>R.</given-names></name>
<name><surname>Black</surname><given-names>S.</given-names></name>
</person-group> (<year>2001</year>) <article-title>ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>281</volume>: <fpage>L1058</fpage>-<lpage>1067</lpage>.</citation>
</ref>
<ref id="bibr213-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weseler</surname><given-names>A.</given-names></name>
<name><surname>Bast</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Oxidative stress and vascular function: implications for pharmacologic treatments</article-title>. <source>Curr Hypertens Rep</source> <volume>12</volume>: <fpage>154</fpage>-<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr214-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wojciak-Stothard</surname><given-names>B.</given-names></name>
<name><surname>Tsang</surname><given-names>L.</given-names></name>
<name><surname>Haworth</surname><given-names>S.</given-names></name>
</person-group>(<year>2005</year>) <article-title>Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> <volume>288</volume>: <fpage>L749</fpage>-<lpage>L760</lpage>.</citation>
</ref>
<ref id="bibr215-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolin</surname><given-names>M.</given-names></name>
<name><surname>Gupte</surname><given-names>S.</given-names></name>
<name><surname>Neo</surname><given-names>B.</given-names></name>
<name><surname>Gao</surname><given-names>Q.</given-names></name>
<name><surname>Ahmad</surname><given-names>M.</given-names></name>
</person-group>(<year>2010</year>) <article-title>Oxidant-redox regulation of pulmonary vascular responses to hypoxia and nitric oxide-cGMP signaling</article-title>. <source>Cardiol Rev</source> <volume>18</volume>: <fpage>89</fpage>-<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr216-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname><given-names>C.</given-names></name>
<name><surname>Cheema</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Suzuki</surname><given-names>Y.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Protein carbonylation as a novel mechanism in redox signaling</article-title>. <source>Circ Res</source> <volume>102</volume>: <fpage>310</fpage>-<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr217-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname><given-names>C.</given-names></name>
<name><surname>Preston</surname><given-names>I.</given-names></name>
<name><surname>Hill</surname><given-names>N.</given-names></name>
<name><surname>Suzuki</surname><given-names>Y.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Iron chelation inhibits the development of pulmonary vascular remodeling</article-title>. <source>Free Radic Biol Med</source> <volume>53</volume>: <fpage>1738</fpage>-<lpage>1747</lpage>.</citation>
</ref>
<ref id="bibr218-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wunderlich</surname><given-names>C.</given-names></name>
<name><surname>Schmeisser</surname><given-names>A.</given-names></name>
<name><surname>Heerwagen</surname><given-names>C.</given-names></name>
<name><surname>Ebner</surname><given-names>B.</given-names></name>
<name><surname>Schober</surname><given-names>K.</given-names></name>
<name><surname>Braun-Dullaeus</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice</article-title>. <source>Pulm Pharmacol Ther</source> <volume>21</volume>: <fpage>507</fpage>-<lpage>515</lpage>.</citation>
</ref>
<ref id="bibr219-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wung</surname><given-names>B.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Chao</surname><given-names>Y.</given-names></name>
<name><surname>Hsieh</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
</person-group>(<year>1999</year>) <article-title>Modulation of Ras/Raf/extracellular signal-regulated kinase pathway by reactive oxygen species is involved in cyclic strain-induced early growth response-1 gene expression in endothelial cells</article-title>. <source>Circ Res</source> <volume>84</volume>: <fpage>804</fpage>-<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr220-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Lin</surname><given-names>M.</given-names></name>
<name><surname>Sham</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Physiological functions of transient receptor potential channels in pulmonary arterial smooth muscle cells</article-title>. <source>Adv Exp Med Biol</source> <volume>661</volume>: <fpage>109</fpage>-<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr221-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yildiz</surname><given-names>P.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Molecular mechanisms of pulmonary hypertension</article-title>. <source>Clin Chim Acta</source> <volume>403</volume>: <fpage>9</fpage>-<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr222-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshizumi</surname><given-names>M.</given-names></name>
<name><surname>Abe</surname><given-names>J.</given-names></name>
<name><surname>Haendeler</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>Q.</given-names></name>
<name><surname>Berk</surname><given-names>B.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species</article-title>. <source>J Biol Chem</source> <volume>275</volume>: <fpage>11706</fpage>-<lpage>11712</lpage>.</citation>
</ref>
<ref id="bibr223-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zou</surname><given-names>M.</given-names></name>
<name><surname>Shi</surname><given-names>C.</given-names></name>
<name><surname>Cohen</surname><given-names>R.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite</article-title>. <source>J Clin Invest</source> <volume>109</volume>: <fpage>817</fpage>-<lpage>826</lpage>.</citation>
</ref>
<ref id="bibr224-1753465812472940">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zuckerbraun</surname><given-names>B.</given-names></name>
<name><surname>George</surname><given-names>P.</given-names></name>
<name><surname>Gladwin</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling</article-title>. <source>Cardiovasc Res</source> <volume>89</volume>: <fpage>542</fpage>-<lpage>552</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>